1	Keeping up with the pathogens: Improved antimicrobial resistance detection and
2	prediction from Pseudomonas aeruginosa genomes
3	
4 5	Danielle E. Madden <sup>1,2</sup> , Timothy Baird <sup>1,2,3</sup> , Scott C. Bell <sup>4,5</sup> , Kate L. McCarthy <sup>6,7</sup> , Erin P. Price <sup>1,2*</sup> and Derek S. Sarovich <sup>1,2*#</sup>
6	
7	$^1$ Centre for Bioinnovation, University of the Sunshine Coast, Sippy Downs, Queensland, Australia
8	<sup>2</sup> Sunshine Coast Health Institute, Birtinya, Queensland, Australia
9	<sup>3</sup> Respiratory Department, Sunshine Coast University Hospital, Birtinya, Queensland, Australia
10	$^4$ Adult Cystic Fibrosis Centre, The Prince Charles Hospital, Chermside, Queensland, Australia
11 12	<sup>5</sup> Children's Health Research Centre, Faculty of Medicine, The University of Queensland, South Brisbane, Queensland, Australia
13	<sup>6</sup> University of Queensland Centre for Clinical Research, Herston, Queensland, Australia
14	<sup>7</sup> Royal Brisbane and Women's Hospital, Herston, Queensland, Australia
15	
16 17	Keywords: Antibiotic, genomics, high-throughput sequencing, bioinformatics, AMR database, metagenomics, whole-genome sequencing, AMR software, AMR prediction
18	
19	Running title: AMR detection from <i>P. aeruginosa</i> genomes
20	
21	#Corresponding author:
22	Derek S. Sarovich
23	dsarovich@usc.edu.au; +61 7 5456 3748

24 \*Authors contributed equally

# 25 Abstract

26	Background: Antimicrobial resistance (AMR) is an intensifying threat that requires urgent mitigation to
27	avoid a post-antibiotic era. The ESKAPE pathogen, Pseudomonas aeruginosa, represents one of the
28	greatest AMR concerns due to increasing multi- and pan-drug resistance rates. Shotgun sequencing is
29	quickly gaining traction for in silico AMR profiling due to its unambiguity and transferability; however,
30	accurate and comprehensive AMR prediction from <i>P. aeruginosa</i> genomes remains an unsolved
31	problem.
32	<i>Methods:</i> We first curated the most comprehensive database yet of known <i>P. aeruginosa</i> AMR
33	variants. Next, we performed comparative genomics and microbial genome-wide association study
34	analysis across a Global isolate Dataset ( <i>n</i> =1877) with paired antimicrobial phenotype and genomic
35	data to identify novel AMR variants. Finally, the performance of our <i>P. aeruginosa</i> AMR database,
36	implemented in our ARDaP software, was compared with three previously published in silico AMR
37	gene detection or phenotype prediction tools – abritAMR, AMRFinderPlus, ResFinder – across both the
38	Global Dataset and an analysis-naïve Validation Dataset ( <i>n</i> =102).
39	<b>Results:</b> Our AMR database comprises 3639 mobile AMR genes and 733 AMR-conferring chromosomal
40	variants, including 75 chromosomal variants not previously reported, and 284 chromosomal variants
41	that we show are unlikely to confer AMR. Our pipeline achieved a genotype-phenotype balanced
42	accuracy (bACC) of 85% and 81% across 10 clinically relevant antibiotics when tested against the
43	Global and Validation Datasets, respectively, vs. just 56% and 54% with abritAMR, 58% and 54% with
44	AMRFinderPlus, and 60% and 53% with ResFinder.
45	Conclusions: Our ARDaP software and associated AMR variant database provides the most accurate
46	tool yet for predicting AMR phenotypes in <i>P. aeruginosa</i> , far surpassing the performance of current
47	tools. Implementation of our ARDaP-compatible database for routine AMR prediction from <i>P</i> .
48	aeruginosa genomes and metagenomes will improve AMR identification, addressing a critical facet in
49	combatting this treatment-refractory pathogen. However, knowledge gaps remain in our
50	understanding of the <i>P. aeruginosa</i> resistome, particularly the basis of colistin AMR.

# 51 Background

52	Antibiotic overuse and misuse [1] has driven the emergence of antimicrobial-resistant (AMR)
53	pathogens globally [2]. We are now on the verge of a 'post-antibiotic era', where simple infections
54	threaten to be untreatable with antimicrobials that once revolutionised modern medicine [3]. If
55	unmitigated, AMR infections are predicted to cause 10 million deaths globally by 2050 and cost
56	USD\$100 trillion per annum [4].
57	The ESKAPE pathogen, Pseudomonas aeruginosa, represents one of the biggest AMR threats due to its
58	intrinsic resistance towards many antibiotics, environmental ubiquity, ability to infect a wide spectrum
59	of hosts, and high global mortality rate [5-7]. Accurately detecting and predicting AMR phenotype
60	from genotype in <i>P. aeruginosa</i> has proven challenging [8], even using machine learning approaches
61	[9], with some approaches as accurate as a coin flip [8]. A major shortcoming of current in silico AMR
62	tools is that they largely focus on detecting AMR gene gain [10, 11] and a small number of
63	chromosomally encoded single-nucleotide polymorphisms (SNPs) [12-14]. However, P. aeruginosa can
64	also evolve AMR through chromosomal insertions-deletions (indels), loss-of-function mutations (e.g.
65	large deletions or frameshift mutations), structural variants, and copy-number variations (CNVs) [15].
66	Despite recent advances [11, 12], most AMR tools remain limited in their scope and accuracy [16] - for
67	example, loss-of-function mutations, a major contributor to AMR, are largely ignored [14], AMR
68	databases are often not species-specific [14, 17], they do not resolve to the individual antibiotic level
69	[11], and precursor mutations conferring reduced antimicrobial susceptibility are overlooked. These
70	limitations are especially problematic for accurate AMR detection and prediction in pathogens
71	encoding complex resistomes like <i>P. aeruginosa</i> [8].
72	To address this gap, we curated and validated the most comprehensive <i>P. aeruginosa</i> -specific AMR
73	variant database yet, which, when used in conjunction with the Antimicrobial Resistance Detection
74	and Prediction (ARDaP) software [14], enables high-accuracy AMR prediction from <i>P. aeruginosa</i>
75	genomes. Performance of our ARDaP-compatible AMR variant database was first assessed across 1877
76	diverse <i>P. aeruginosa</i> strains ("Global Dataset"), and subsequently, across 102 analysis-naïve <i>P.</i>

- 77 *aeruginosa* strains ("Validation Dataset"). Our approach, which we demonstrate far exceeds the
- 78 performance to current AMR prediction software, provides a crucial steppingstone towards the
- routine clinical use of genomics and metagenomics to inform personalised *P. aeruginosa* antimicrobial
- 80 treatment regimens.

#### 81 Methods

- 82 *P. aeruginosa* AMR variant database construction. To cover the spectrum of AMR variants found in *P.*
- 83 *aeruginosa*, an ARDaP v1.9 [14] compatible SQLite database was populated with all known AMR
- 84 variants described in this pathogen to date
- 85 (https://github.com/dsarov/ARDaP/blob/master/Databases/Pseudomonas aeruginosa pao1/). Gene
- 86 names, locus tags, and genomic coordinates in our AMR variant database were based on PAO1
- 87 (NC\_002516.2) [18]. An exhaustive literature search was conducted to encompass biomedical
- 88 literature published from 1980 to April 20<sup>th</sup> 2023 within the MEDLINE database. Search terms included
- 89 "antimicrobial resistance" and "P. aeruginosa" accompanied by a variable search term for targeted
- 90 literature, and included either: i) antibiotic class (e.g. carbapenem, aminoglycoside); ii) AMR
- 91 mechanism (e.g. efflux, gene expression enzymatic inactivation); or iii) a known AMR gene (e.g. oprD,
- 92 *ampC*, gyrA).
- 93 The resultant *P. aeruginosa* AMR database (Dataset 1) consists of three tables. The first table, '1.
- 94 Antibiotics', lists the ten clinically relevant antibiotics that were interrogated in our study: amikacin,
- 95 cefepime, ceftazidime, ciprofloxacin, colistin, imipenem, meropenem, piperacillin,
- 96 piperacillin/tazobactam, and tobramycin, whether these drugs are first-line, second-line or tertiary,

97 and their associated antibiotic class. The second ('2. Variants\_SNP\_indel') and third ('3. Coverage')

tables list the entire *P. aeruginosa* mutational resistome [19, 20], which includes all known genetic

99 alterations that can lead to AMR, including the functional loss of chromosomal genes (under, '3.

100 Coverage'). These databases include all AMR variants and genes that: i) cause efflux pump

101 upregulation [21]; ii) alter outer membrane permeability [22]; iii) de-repress or alter the substrate

range of the AmpC cephalosporinase [23]; and/or iv) alter the antimicrobial target [24]. AMR gene

acquisition was interrogated with ResFinder v4.0 [25], using default parameters and retaining only

104 genes identified at 100% similarity and with 100% coverage. Resfinder is integrated within the ARDaP

- tool and run as part of the default pipeline. The default ResFinder database was manually curated to:
- 106 1) remove false-positive hits that were consistently identified in AMR sensitive strains; *bla*<sub>OXA-</sub>

107  $_{395\_1\_AY306133}$ ,  $bla_{OXA-396\_1\_AY306134}$ ,  $bla_{PAO\_4\_AY083592}$ ,  $bla_{PAO\_1\_AY083595}$ ,  $bla_{PAO\_3\_FJ666073}$ ,  $bla_{PAO\_2\_FJ666065}$ , and

108 *crpP\_*HM560971; 2) include additional gene variants identified within the Global Dataset in

aminoglycoside AMR-conferring genes *aac*(6')-lb, *aac*(6')-lla, *aac*(6')-lb-cr, and *aac*(3)-llla; and 3) as per

110 ResFinder recommendations for *P. aeruginosa*, the substrate range for *bla*<sub>OXA-2\_1\_DQ112222</sub> and *bla*<sub>OXA-</sub>

111 2\_2\_GQ466184 was expanded to include meropenem and imipenem.

112 For the aminoglycosides (i.e. amikacin and tobramycin), known AMR variants consisted of point

113 mutations in *algA* [26], *amgS* [27], *fusA1* [26, 28-33], *rplB* [34], *ptsP* [33, 35], and *tuf1* [26], and loss-of-

114 function mutations in the *nuo* [36-38] pathway. For the carbapenems (i.e. imipenem and meropenem),

115 cephalosporins (i.e. ceftazidime), and β-lactams with or without an inhibitor (i.e. piperacillin and

piperacillin/tazobactam), mutations that alter or expand the substrate range of the *ampC* 

117 cephalosporinase [23, 39-42] or that alter *ampC* expression, including inactivation of penicillin-

118 binding-protein 4 (PBP4; dacB) [43-45], ampD [45-47], ampDh2 [47], ampDh3 [47], ampE [47], ampR

119 [48, 49], mpl [50], or ampC-ampR intergenic region [51], mutations in PBP3 (ftsl) [48, 52, 53], and

120 mutations that cause oprD loss, inactivation, or down-regulation [49, 54-60], were included. For

121 ciprofloxacin AMR prediction, we included point mutations in gyrA [61-67], gyrB [62, 63, 65, 68], parC

122 [61-63, 66], and parE [62, 63, 65]. For colistin AMR prediction, point mutations in cprS [52], pmrA [69],

123 *pmrB* [31, 69-74], *phoP* [69], and *phoQ* [69] were included.

124 Efflux pumps play a key role in AMR development in *P. aeruginosa*, predominantly through regulator 125 alterations, which drive efflux pump over expression [15]. To predict MexAB-OprM upregulation, which 126 is associated with  $\beta$ -lactam (including carbapenem) AMR [21], we included mutations in the *cis* (*mexR* 127 [29, 61, 64, 75, 76]) and trans (nalC [77, 78] and nalD [23, 71, 77-79]) regulators of this efflux pump. 128 For MexCD-OprJ upregulation, which is associated with fluoroquinolone and specific  $\beta$ -lactam AMR 129 [21], mutations and loss-of coverage in the single known regulator, nfxB [61, 64] were included. For 130 MexEF-OprN upregulation, which is linked to fluoroquinolone AMR [21], we included function-altering 131 mutations or loss of coverage in mexS [80], the LysR family regulator mexT [81], and the global 132 regulator mvaT [82]. For MexXY upregulation, which is associated with aminoglycoside and

fluoroquinolone AMR, we included loss-of-coverage in two refined regions of *mexZ* [83, 84] and the intergenic region (*mexOZ*) between *mexZ* and *mexX* [85, 86]. Additionally, functional gene loss variants across the entire *P. aeruginosa* chromosome, identified via transposon insertion experiments [36, 38, 87], were included.

In addition to variants that confer AMR, mutations in essential AMR-conferring genes that cause
unusual antimicrobial susceptibility were included: efflux pumps *mexAB* [88, 89], *mexXY* [90], *mexCD*[91] and *mexEF* [82, 92], and the *ampC* regulators *ampP* and *ampG*, which are required for high-level *ampC* expression [51]. We also included additional targets for (meta)genome quality control and *P*. *aeruginosa* speciation (*ecfX* [93]), and genes responsible for conferring a hypermutator phenotype
(*mutS*, *mutL* and *uvrD* [94]).

Global Dataset. To comprehensively capture geographic, genomic, and phenotypic diversity, we
collated a large and comprehensive *P. aeruginosa* isolate collection (*n*=1877) of all publicly available
strains with paired antimicrobial phenotype and genomic data [9, 20, 32, 54, 95-103] (Dataset 2, Table
S1). This dataset includes many antimicrobial-susceptible strains, which are essential for developing
and refining high-quality AMR databases [14, 104]. Isolates with minimum inhibitory concentration
(MIC) data were reclassified as sensitive, intermediate, or resistant using the CLSI M100S-Ed32:2022
guidelines.

150 Validation Dataset. To independently evaluate AMR software performance, we examined 102

151 phylogenetically diverse, analysis-naïve, clinical *P. aeruginosa* strains (Figures S1 and S2). Isolates were

obtained from people admitted to hospitals in Qld, Australia, with cystic fibrosis (CF; n=42),

bacteraemia (n=35), chronic obstructive pulmonary disease (COPD; n=21), bronchiectasis (n=1), ear

154 infection (*n*=1), ulcer (*n*=1), or urinary tract infection (*n*=1), between 2008 and 2020 (Table S2). Eighty-

155 four isolates have previously been genome-sequenced (NCBI BioProject PRJNA761496; GenBank

accessions NSXK00000000.1 and NSZK00000000.1) and some have previously undergone antimicrobial

susceptibility testing [105, 106]. For the current study, 18 additional COPD isolates (SCHI0038.S.1,

158 SCHI0050.S.3, SCHI0058.S.1, SCHI0058.S.2, SCHI0059.S.1, SCHI0064.S.1, SCHI0065.S.1, SCHI0068.S.3,

159 SCHI0070.S.1, SCHI0070.S.1, SCHI0084.S.1, SCHI0098.S.1, SCHI0103.S.1, SCHI0107.S.1, SCHI0109.S.1,

160 SCHI0109.S.2, SCHI0112.S.1, SCHI0112.S.2) were sequenced and appended to BioProject

161 PRJNA761496. Antimicrobial susceptibility profiles for 8 of 10 clinically-relevant antibiotics were

162 determined across the Validation Dataset (Table S2) using disc diffusions, following CLSI M100S-

163 Ed32:2022 guidelines. Meropenem and ciprofloxacin MICs were determined by ETEST (bioMérieux,

164 Murarrie, Australia) using sensitive, intermediate, and resistant MIC cut-offs of  $\leq$ 4, 8, and  $\geq$ 16 µg/mL

for meropenem, and  $\leq 0.5$ , 1, and  $\geq 2 \mu g/mL$  for ciprofloxacin. PAO1 (Belgian Coordinated Collection of

166 Microorganisms [BCCM], Ghent University, Belgium) and LMG 6395 (BCCM) were included as

167 antimicrobial-susceptible controls.

168 Microbial genome-wide association study (mGWAS) and machine learning (ML) for AMR prediction.

169 To identify novel AMR variants, mGWAS [107] was performed on the Global P. aeruginosa Dataset

170 (*n*=1877 strains), with SNPs and indels identified using SPANDx v4.0.1 [108]. To increase the signal-to-

171 noise ratio, variants found in antimicrobial-sensitive isolates were penalised four-fold compared with

172 AMR strains due to a presumed large effect size [109]. The top 50 variants associated with each AMR

173 phenotype were assessed for their ability to improve phenotype prediction; those that improved

174 phenotype prediction were included in the AMR database. Additionally, a supervised ML approach was

175 performed using the Global Dataset and the AMR database as features for model creation.

176 **Comparative genomic analysis.** To identify additional novel AMR variants, we conducted a

177 comparative genomic analysis using SPANDx, with a focus on AMR strains that did not encode a known 178 AMR variant (i.e. false negatives). These strains were compared to their closest antimicrobial-sensitive 179 relative(s) as determined by the whole-genome phylogenetic analysis (Figure S1). SNPs and indels that 180 separated AMR from antimicrobial-sensitive strain/s were identified, annotated and investigated with 181 manual inspection to prioritise mutations in known AMR genes. Candidate variants were then tested 182 against the Global Dataset to determine whether they improved phenotype prediction. AMR variants 183 that increased balanced accuracy (bACC) were included in the database; those that did not alter, or 184 that decreased bACC, were discarded.

185 AMR prediction analysis. AMR prediction was performed using our P. aeruginosa AMR database

186 (v1.0), implemented in ARDaP [110]. ARDaP was chosen as it is the only AMR software that can detect

all mutation types (i.e. SNPs, indels, gene gain, gene loss, frameshift mutations, structural variants,

and CNVs) [14]. ARDaP also has a built-in feature that automatically generates a clinician-friendly

antimicrobial susceptibility summary report for each strain (Figure S3) to simplify in silico AMR

- 190 interpretation [14]. ARDaP performance was compared against four tools for AMR phenotype
- 191 prediction and/or AMR variant identification: abritAMR [111], RGI v5.1.0 and CARD v3.0.9 [11],
- 192 ResFinder v4.1 [10], and AMRFinderPlus v3.8.28 [112]. As abritAMR and AMRFinderPlus frequently

report predicted AMR phenotypes to the antibiotic class level only, we chose to interpret AMR variant

- 194 presence for a given class as conferring AMR towards all antibiotics within that class. Importantly,
- 195 AMRFinderPlus is not intended for clinical phenotype prediction
- 196 (https://github.com/ncbi/amr/wiki/Interpreting-results#genotype-vs-phenotype) but has been

197 included as a benchmark for gene detection accuracy. For the purposes of software comparisons, gene

198 identification by AMRFinderPlus was interpreted as conferring phenotypic resistance.

199 A variant scoring scheme has previously been described by Cortes-Lara and colleagues, which 200 employed a 0 (no effect) through 1 (EUCAST AMR) scale to predict in silico AMR profiles [102]. We 201 expanded upon this scheme by providing an automated weighted score for all AMR variants in our 202 database that quantifies their contribution, positive or negative, towards AMR development (Dataset 203 1, 'Threshold' column); this score is recorded for each antibiotic on ARDaP's automatically generated 204 clinician-friendly report (Figure S3), unlike the Cortes-Lara scheme, which requires manual scoring for 205 each antibiotic and strain [102]. Using our scoring system, variants known to cause AMR in isolation 206 score as 100%, whereas AMR variants known to confer AMR in a stepwise manner (that is, only when 207 in combination with other variant/s), or that only result in intermediate resistance, are given a lower 208 score (e.g. 40-50%). This method accounts for both the additive nature of chromosomal mutations in 209 P. aeruginosa, and for the decreased AMR potential caused by loss of efflux pumps or essential

210 transcriptional regulators. Acquired AMR genes identified by Resfinder within ARDaP were considered

to confer full AMR, i.e. are scored at 100% for the purposes of phenotype prediction.

- 212 Intermediate resistance prediction. The capacity of our AMR variant database to predict intermediate
- resistance phenotypes was examined against the Global Dataset using the following criteria:
- A true-positive prediction occurred when either: i) an AMR strain was classed as AMR, or ii) an
   intermediate strain was identified as intermediate;
- A true-negative prediction occurred when an antimicrobial-sensitive strain was identified as
   antimicrobial sensitive;
- A false-positive prediction occurred when either: i) an antimicrobial-sensitive strain was
- classed as intermediate or AMR, or ii) an intermediate strain was classed as AMR; and
- A false-negative prediction occurred when either: i) an intermediate strain was classed as
   antimicrobial-sensitive, or when an AMR strain was predicted to be antimicrobial-sensitive or
   intermediate.
- These rules provided the strictest evaluation criteria for the assessment of ARDaP's ability to identify intermediate strains. Only ARDaP's intermediate resistance prediction performance was assessed as abritAMR, AMRFinderPlus, CARD, and ResFinder all lack the capacity to identify intermediate resistance.

227 AMR software predictive performance in *P. aeruginosa*. Due to its inability to predict AMR towards 228 individual antibiotics, and a very high rate of false-positive predictions in the Global Dataset, CARD was 229 deemed unsuitable for P. aeruginosa AMR analysis and was excluded from further assessment. For all 230 other tools, predictive performance was determined using bACC [113, 114], which averages sensitivity 231 [i.e. true positives/(true positives + false negatives)], and specificity [i.e. true negatives/(true negatives 232 + false positives)]. This metric was chosen as it accounts for dataset imbalance; that is, it minimises 233 over- or under- representation of antimicrobial-sensitive or AMR strains that may otherwise make 234 certain tools appear better or worse due to inherent dataset bias [8]. Additionally, we compared recall

- 235 (AMR) [true positives/(true positives + false negatives], precision (AMR) or positive predictive value
- 236 (PPV) [true positives/(true positives + false positives), recall (sensitivity) [true negatives/(true
- 237 negatives + false positives) and precision (sensitivity) or negative predictive value (NPV) [true
- 238 negatives/(true negatives + false negatives)] across all software tools.

239 Results

240 *P. aeruginosa* AMR variant identification and refinement. An extensive literature search was

241 undertaken to identify all known and putative chromosomal variants that lead to AMR in P.

- 242 aeruginosa. Among the 733 identified chromosomal AMR variants, 284 putative variants were
- 243 classified as 'natural variation' as they were common in both antimicrobial-sensitive and AMR strains
- in our Global Dataset, and therefore deemed unlikely to contribute to an AMR phenotype. Most of

these naturally occurring variants had been previously reported as putatively causing AMR, with little

- to no functional investigation. Importantly, no functionally validated AMR driving variants were re-
- classified as 'natural variation'. Next, using mGWAS and comparative genomic analyses of the Global
- 248 Dataset, we identified 75 previously unreported AMR variants associated with one or more AMR
- phenotypes (Table 2). In total, we identified 736 chromosomal variants in known AMR loci (Dataset 2),
- of which 374 were associated with AMR and 284 were natural variation.

251 Predictive performance across Global Dataset. Although superior to CARD, abritAMR, AMRFinderPlus,

- and ResFinder still showed relatively poor bACCs for most antibiotics, with average bACCs of between
- 253 56 and 60%, well below ARDaP's average bACC of 85% (Figure 1A).
- 254 The best abritAMR, AMRFinderPlus, and ResFinder predictions were achieved for the aminoglycosides,
- with average bACCs of 75%, 75%, and 82%, respectively, although these rates were lower than
- ARDaP's average aminoglycoside bACC of 92%. abritAMR, AMRFinderPlus, and ResFinder AMR
- 257 prediction for all other antibiotics showed poor to very poor bACCs. AMRFinderPlus had a bACC of just
- 258 50% for the penicillins, cephalosporins, and colistin the same predictive capacity as a coin flip and
- had only a slightly better bACC for ciprofloxacin (58%), imipenem (58%), and meropenem (61%).

ResFinder also had a bACC of just 50% for cephalosporins and colistin, and performed worse for
carbapenems (average bACC of 50%) than AMRFinderPlus, although it was better for penicillins
(average bACC of 62%) and ciprofloxacin (bACC of 62%). abritAMR was the worst at predicting
penicillin phenotypes, with an average bACC of just 43%, worse than a coin flip; its performance was
otherwise identical to AMRFinderPlus. In contrast, ARDaP surpassed abritAMR, AMRFinderPlus, and
ResFinder across all 10 antibiotics, with bACCs ranging from 60% (colistin) to 94% (tobramycin) (Figure
1A).

267 Predictive performance across Validation Dataset. We next tested abritAMR, AMRFinderPlus, ARDaP,

and ResFinder across the Validation Dataset of 102 Australian clinical *P. aeruginosa* strains (Table S2)

to determine each software's performance in an analysis-naïve dataset. As no strains in the Validation

270 Dataset displayed colistin AMR, the bACC for this antibiotic could not be assessed. These strains

otherwise exhibited similar AMR rates to the Global Dataset, ranging from 26% for meropenem to 58%
for piperacillin (Table S4).

273 Overall, ARDaP had high predictive accuracy (average bACC of 81%) across all antibiotics (Figure 1B),

vastly outperforming ResFinder (average bACC of 53%), abritAMR, and AMRFinderPlus (average bACC
of 54% each). Notably, the ResFinder meropenem bACC, at just 43%, yielded worse performance than
a coin flip.

277 Inclusion of the novel AMR variants identified in the Global Dataset. The inclusion of these markers

increased Validation Dataset sensitivity by an average of 4% (range 0 to 27%) depending on antibiotic,

279 with the sensitivity of most antibiotics (meropenem, imipenem, ciprofloxacin, cefepime, and

piperacillin/tazobactam) remaining unchanged. Amikacin increased the most (27%) due to the

inclusion of a SNP in *rplB* (Gly138Ser), followed by tobramycin at 4%, and piperacillin and ceftazidime
at 3% each."

ARDaP performance between the Global and Validation Datasets. Whilst ARDaP bACC between the
 datasets were broadly similar, there was a greater proportion of false-positive and false-negative

variants encoding AMR towards piperacillin (32% difference), tobramycin (24% difference), cefepime

286 (19% difference), amikacin (12% difference), and meropenem (9% difference) in the Validation

287 Dataset. In contrast, there was a greater proportion of false-positive and false-negative variants

288 encoding amikacin AMR (5% difference) in the Global Dataset (Figure 1).

289 Comparative genomic analysis of Validation Dataset isolates that yielded false-negative

aminoglycoside AMR predictions identified that many belonged to a single multilocus sequence type

291 (ST), ST801, also known as AUST-06. Among 23/24 aminoglycoside-AMR ST801 isolates, a clade-

specific missense variant in elongation factor G (FusA1 S459F) was identified; this SNP was not

293 observed in other Global or Validation Dataset isolates. The remaining aminoglycoside-AMR ST801

strain, SCHI0010.S.1, encoded AAC(6')-Ila, an aminoglycoside-modifying enzyme. Inclusion of FusA1

295 S459F into our AMR database significantly increased ARDaP bACCs for the Validation Dataset by an

average 19% for both amikacin and tobramycin, raising them to 95% and 90%, respectively, with no

297 impact on Global Dataset bACC.

Precision and recall among AMR software. ARDaP demonstrated excellent precision and recall for predicting antimicrobial-sensitive and AMR phenotypes, ranging from 73% (average AMR recall) to 96% (average sensitivity recall) (Figure 2A). In contrast, abritAMR ranged from 54% (average AMR precision) to 62% (average sensitivity precision) (Figure 2B), AMRFinderPlus ranged from 54% (average AMR precision) to 62% (average AMR recall) (Figure 2C), and ResFinder ranged from only 42% (average AMR precision) to 68% (average sensitivity precision) (Figure 2D).

304 For colistin, abritAMR, AMRFinderPlus, and ResFinder all yielded AMR precision and recall values of

305 0%; in other words, none of these tools identified colistin AMR variants in strains exhibiting a colistin

306 AMR phenotype. In comparison, ARDaP identified colistin AMR strains with 21% recall and 100%

307 precision. Similarly, abritAMR, AMRFinderPlus, and ResFinder all failed to predict cefepime sensitivity

308 in any cefepime-sensitive strain (Figures 2B-2D), instead erroneously classing every strain as cefepime-

309 resistant, whereas ARDaP correctly identified cefepime-sensitive strains with 96% precision and 96%

- recall (Figure 2A). All three tools also failed to predict ceftazidime sensitivity. In addition, abritAMR
- and AMRFinderPlus failed to identify piperacillin sensitivity in any of the tested strains, and
- 312 AMRFinderPlus yielded failed to identify piperacillin/tazobactam sensitivity (Figures 2B and 2C).
- 313 **Predictive performance for intermediate resistance.** The inclusion of isolates with intermediate
- resistance reduced ARDaP bACCs by between 1 to 13% (6% average), depending on the antibiotic
- 315 (Table S5). Intermediate resistance inclusion was most detrimental to cefepime AMR prediction (-
- 316 13%), followed by imipenem (-8%), meropenem, ciprofloxacin and ceftazidime (-7%),
- 317 piperacillin/tazobactam and amikacin (-5%), piperacillin (-4%) and tobramycin (-1%). Colistin prediction
- 318 was unchanged as no intermediate category exists for this antibiotic.

## 319 Discussion

320	The increasing role of high-throughput sequencing in the clinic has driven the concomitant
321	development of bioinformatic tools for AMR variant detection and antimicrobial phenotype prediction
322	[115]. However, current gold standard AMR tools are limited in their accuracy and performance due to
323	their heavy focus on AMR gene gain rather than AMR-conferring chromosomal variants, and their
324	inability to detect the gamut of genetic mutations that can confer AMR (i.e. gene loss, indels, CNVs,
325	and structural variants) [14]. In addition, most tools have primarily focused on detection of AMR genes
326	rather than AMR phenotype prediction. These shortcomings become acutely evident when attempting
327	to predict AMR in pathogens with complex resistomes like <i>P. aeruginosa</i> [8].
328	To address this issue, we first constructed a comprehensive and accurate database of AMR variants
329	encoded by <i>P. aeruginosa</i> . Our database of 733 chromosomal AMR-conferring variants (Dataset 2)
330	comprises 374 previously identified AMR variants that we confirmed were significantly associated with
331	an AMR phenotype, along with 75 AMR variants identified in this study. A further 284 AMR variants
332	identified by us, and others, were classed as natural variants due to their non-significant association
333	with AMR strains (Table S3). These variants were included for two reasons: i) to allow ARDaP's
334	coverage algorithm to scan known AMR genes for novel, high-consequence mutations (e.g. frameshift
335	mutations in <i>oprD</i> that lead to carbapenem AMR) while avoiding natural variation that does not
336	impact function, ii) to substantially reduce the legwork involved in identifying putative novel AMR
337	variants using mGWAS or comparative genomics, and iii) to reduce the over-reporting of natural
338	variants as putatively AMR conferring. Our natural variant list also provides a valuable resource for
339	minimising erroneous AMR variant reporting in future <i>P. aeruginosa</i> AMR variant discovery studies.
340	Next, performance assessment of our ARDaP-compatible AMR database against the Global and
341	Validation Datasets showed that our tool outstripped the predictive performance of current 'gold
342	standard' AMR software across all 10 antibiotics, yielding average bACC of 85%, vs. just 56%, 58% and
343	60% for abriTAMR, AMRFinderPlus and ResFinder, respectively (Figure 1). This performance difference
344	is due to our chromosomal AMR variant database, which directly links genotypes with individual

345 antibiotic phenotypes, and provides weighted scores on variant contribution towards AMR

346 development (Dataset 1). Our findings concur with a recent study of 654 *P. aeruginosa* genomes,

347 which also found that CARD and ResFinder exhibited poor AMR prediction performance metrics across

348 all 11 tested anti-pseudomonal antibiotics [8].

349 Although still inferior to ARDaP, abritAMR, AMRFinderPlus, and ResFinder performed best when 350 predicting aminoglycoside phenotypes in the Global Dataset (Figure 1A), which is heavily populated 351 with American and European strains (Table S1). These tools performed substantially worse when 352 tested against the Australian Validation Dataset (Figure 1B), with the average aminoglycoside bACC 353 dropping by 16% for AMRFinderPlus and 26% for ResFinder. ARDaP's bACC also initially dropped by 354 18% for the aminoglycosides. Upon closer inspection, we found that this performance reduction was 355 predominantly due to false-negative calls among the ST801 isolates, a geographically restricted clone 356 that has only been reported in people with CF in Qld, Australia [116]. Inclusion of one novel fusA1 357 variant identified with comparative genomics in our AMR variant database restored ARDaP's 358 performance to bACC of 90% and 95% for amikacin and tobramycin, respectively. This performance 359 difference across isolate datasets can be attributed to two phenomena. The first is the predominance 360 of aminoglycoside-modifying enzymes in the Global (33%) but not Validation (8%) Datasets, reflecting 361 potential major differences in the geographic prevalence of these enzymes that requires further 362 exploration. The second is the enrichment of CF-derived isolates in the Validation Dataset, which 363 comprise 86% of the aminoglycoside AMR strains (Figure S1). These isolates have largely developed 364 aminoglycoside AMR via chromosomal mutation rather than aminoglycoside-modifying enzyme 365 acquisition; as such, abritAMR, AMRFinderPlus, and ResFinder exhibited poor aminoglycoside AMR 366 predictive capacity due to their limited chromosomal AMR variant databases. These performance 367 differences highlight the need for including isolates from diverse sources, disease states, and locales to 368 provide the most relevant AMR prediction software benchmarking comparisons. Our results suggest 369 that abritAMR, AMRFinderPlus, and ResFinder are not useful for predicting aminoglycoside AMR from

370 CF-derived *P. aeruginosa*, particularly in the Australian context, although this finding requires further 371 exploration across larger, geographically diverse datasets.

372 Our findings revealed important weaknesses in abritAMR, AMRFinderPlus, and ResFinder when used 373 for phenotype prediction. All three tools yielded bACCs of just 50% for cephalosporin prediction, 374 abritAMR and AMRFinderPlus yielded a bACC of just 50% for piperacillin (Figures 1A and 1B), and 375 abritAMR performed worse than a coin flip for predicting piperacillin/tazobactam phenotypes, with a 376 bACC of just 35%. These cases of under-performance were largely attributed to sensitive isolates being 377 predicted as AMR (Figure 2). The inferior performance of abritAMR and AMRFinderPlus over ResFinder 378 was further exacerbated by their software design; for most anti-pseudomonal antibiotics, these tools 379 only predict phenotypes to the antibiotic class level. To facilitate direct software comparisons, AMR 380 identified for a given antibiotic class by abritAMR and AMRFinderPlus was extrapolated to all 381 antibiotics within that class, which likely led to higher imprecision or error due to differences in within-382 class antibiotic spectrum of activity. For instance, the poor abritAMR piperacillin/tazobactam bACC 383 may be attributed to this tool only reporting ' $\beta$ -lactamase' presence; however, the impact of this  $\beta$ -384 lactamase on piperacillin/tazobactam efficacy is not explicitly reported due to insufficient granularity. 385 Based on our and other's [8] collective findings, we strongly discourage the use of abritAMR, 386 AMRFinderPlus, or ResFinder for in silico cephalosporin AMR prediction in *P. aeruginosa* as none of 387 these tools are currently capable of accurately differentiating sensitive from AMR strains for these 388 antibiotics. Further, abritAMR and AMRFinderPlus should not be used to predict penicillin 389 susceptibility phenotypes in *P. aeruginosa* due to their insufficient resolution. 390 Colistin prediction proved the most challenging of the 10 tested antibiotics, yielding bACCs of 50% 391 with abriTAMR, AMRFinderPlus, and ResFinder, and 60% with ARDaP. ARDaP the only tool able to 392 correctly predict some colistin AMR strains; the other three tools erroneously classified all P. 393 aeruginosa strains as colistin-sensitive (Figures 2B and 2C). Accurate colistin prediction may have been 394 hampered by the purported unreliability of gradient diffusion methods (e.g. disc diffusions, ETESTS) to 395 accurately measure colistin breakpoints due to poor antibiotic diffusion and Mueller-Hinton agar

manufacturer differences [117, 118]. Our study has identified a major gap in understanding the basis
of colistin AMR, and underscores the need for much more work in this area, especially given the
increasing use of inhaled colistin in treatment-refractory, multidrug-resistant *P. aeruginosa* infections
[119, 120].

400 Loss-of-function mutations affecting the specialised porin, OprD, are the most common cause of 401 carbapenem AMR in *P. aeruginosa*, particularly in clinical isolates [9]. Although oprD is notoriously 402 hypervariable [121], ARDaP's ability to accurately identify functional OprD loss accounted for its high 403 carbapenem predictive accuracy (average bACC of 89% vs. just 61% for AMRFinderPlus and 52% for 404 ResFinder). This outcome highlights the complex nature of the *P. aeruginosa* resistome, the necessity 405 of AMR variant curation efforts, the value of AMR prediction tools that can accurately detect the 406 spectrum of chromosomal variants, and the value of species-specific AMR variant databases to achieve 407 the most accurate AMR predictions.

408 Mutations leading to chromosomal cephalosporinase (*ampC*) overexpression are an important cause 409 of  $\beta$ -lactam AMR [15, 122]. To predict *ampC* upregulation, our database includes function-altering 410 mutations in genes known to directly or indirectly regulate *ampC*. These chromosomally-encoded 411 variants, alongside acquired cephalosporinases, accounted for the high average ARDaP bACC observed 412 for the cephalosporins (84% vs. just 50% with abritAMR, AMRFinderPlus, and ResFinder; Figure 1). The 413 prominence of *ampC* over-expression-associated determinants provides further support that this 414 mechanism is a major cause of acquired cephalosporin AMR, particularly in clinical P. aeruginosa 415 isolates [122, 123]. In support of this hypothesis, Khaledi and colleagues demonstrated a considerably 416 higher bACC for ceftazidime AMR prediction when using both transcriptomic and genomic data (82%) 417 compared with just genomic data (67%) [9]. Genomics alone cannot currently identify all instances of 418 *ampC* over-expression, either because up-regulation is the result of an epigenic change, or the 419 mutation remains cryptic due to an incomplete understanding of *ampC* regulatory mechanisms. 420 Indeed, a review of intrinsic  $\beta$ -lactamases by Juan and colleagues details the complexity of *ampC* 421 expression and its intricate regulation, along with the challenge of corresponding elevated  $\beta$ -

lactamase MICs driven by *ampC* upregulation to clinical AMR breakpoints [124]. Using a combination
of genomic and transcriptomic data will likely lead to further improvements in AMR prediction for
most antibiotics [9, 122].

425 Predicting intermediate resistance is exceedingly difficult from genomic data alone, even with complex 426 machine learning algorithms that combine transcriptomic and genomic data [9]. We also encountered 427 difficulties in predicting intermediate resistance, with the inclusion of intermediate strains dropping 428 bACCs by up to 13% (Table S5). Possible explanations include the need to understand the contribution 429 of stepwise variants in conferring decreased antibiotic susceptibility [15, 67, 125], subtle and rapidly 430 reversible gene expression alterations [9] caused by methylation [126] or dynamic environmental 431 stimuli, and undetected strain mixtures. Further refinement of our ARDaP-compatible database, such 432 as capacity to analyse RNA-seq data, will continue to improve this critical yet understudied area. 433 Nevertheless, the pioneering capacity of ARDaP to predict intermediate resistance, including stepwise 434 mutations that lower the barrier to full AMR development, and to differentiate strain mixtures in 435 metagenomic data, has important implications for detecting emerging AMR in *P. aeruginosa* and 436 informing earlier treatment shifts [14].

437 Errors introduced during sample collection, metadata curation, specimen processing, or sequencing 438 may be partially responsible for our inability to predict AMR with a 100% bACC for any antibiotic. For 439 example, 11 strains in the Khaledi et al. dataset [9] possessed variants known to confer ceftazidime AMR (e.g. *bla*<sub>VIM-[2,4,47]</sub>, *bla*<sub>OXA-2</sub>, *bla*<sub>GES-[1,5]</sub>) yet were reported as ceftazidime-sensitive, and 22 strains in 440 441 the Kos et al. dataset were amikacin-sensitive, yet possessed the aminoglycoside-modifying enzyme 442 gene *aac(6')-lb-cr*, known to cause amikacin AMR and reduced ciprofloxacin susceptibility [127]. Due 443 to the presence of these known AMR variants, all tools identified these strains as AMR, contributing to 444 imperfect bACC (Figure 1) and poor precision (Figure 2) for amikacin and ceftazidime. As we did not 445 have access to these strains, it was not possible to retest their AMR phenotypes or to repeat genome 446 sequencing; however, we hypothesise that these strains would generate different results upon 447 phenotypic retesting or re-sequencing. Alternatively, these AMR variants may be present but

functionally or transcriptionally inactive, resulting in false-positive predictions for these isolates that
must be factored into future AMR prediction estimates.

450 We recognise several study limitations. First, some false-positive predictions were identified across all 451 antibiotic classes with our ARDaP-compatible database; however, these rates were significantly lower 452 than those reported by other software (Figure 1). Whilst not ideal, we chose to retain a small number 453 of AMR variants that result in low-frequency false-positive predictions as: i) some strains may have 454 reverted to a sensitive phenotype, despite encoding a known AMR variant; and ii) we included 455 phenotypic data generated by others, which may harbour inaccuracies. Functional profiling will be 456 essential to fully understand the contribution of each of these variants in conferring AMR. Second, 457 although we aimed for a phylogenetically diverse Validation Dataset (Figure S1, S2), only isolates from 458 Queensland, Australia, were included in this dataset, limiting geographic and genetic representation. 459 Despite this shortcoming, the Validation Dataset proved extremely useful for identifying AMR variant 460 database deficits across all three AMR tools, particularly those variants encoding AMR towards the 461 aminoglycosides, piperacillin, cefepime, and meropenem, highlighting clear areas of need for future 462 research efforts. Third, due to cost constraints, we only performed ciprofloxacin and meropenem 463 ETESTs for the Validation Dataset isolates, with disc diffusions used for the remaining eight antibiotics, 464 a less robust methodology that may have led to some minor discrepancies in antimicrobial phenotype assignments. Fourth, we did not test out ARDaP's capacity to identify *P. aeruginosa* AMR variants from 465 466 simulated and real metagenomic datasets and strain mixtures for this study as we have proven this 467 capacity elsewhere [14, 106] nor were we able to compare software performance against ARESdb 468 [128] due to the proprietary nature of this database. Finally, our study would have benefitted from the 469 inclusion of transcriptomic data [9] to identify additional novel variants associated with AMR. Although 470 our understanding of the molecular mechanisms of AMR in *P. aeruginosa* is improving rapidly in the 471 genomics era, false-negative predictions still occur across all antibiotic classes. Using ARDaP, such 472 false-negative strains can now be rapidly identified and targeted for future functional work to pinpoint 473 novel AMR variants and mechanisms.

## 474 Declarations

475	Ethics approval and consent to participate. Clinical specimen collection was approved by The Prince
476	Charles Hospital (HREC/13/QPCH/127 and HREC/2019/QPCH/48013) and Royal Brisbane and Women's
477	Hospital (DA: jl) Human Research Ethics Committees. Participants with CF or COPD provided written
478	consent; a waiver of informed consent was approved for other specimens due to a low-to-negligible
479	risk assessment.
480	Consent for publication. Not applicable.
481	Availability of data and materials. The datasets supporting the conclusions of this article are available
482	in the NCBI GenBank (references NSXK00000000.1 and NSZK0000000.1) and Sequence Read Archive
483	database via BioProject accession PRJNA761496 (Validation Dataset), and BioProject accessions
484	PRJEB15036, PRJEB21341, PRJEB29539, PRJEB14771, PRJNA297679, PRJNA317143, PRJNA526797,
485	PRJNA264310, PRJNA388357, PRJNA793523, PRJEB40140 and PRJNA532924 (Global Dataset). The <i>P.</i>
486	aeruginosa AMR database constructed for this study is freely available at:
487	https://github.com/dsarov/ARDaP/tree/master/Databases/Pseudomonas_aeruginosa_pao1. The
488	ARDaP software is freely available at: <u>https://github.com/dsarov/ARDaP</u> . All code used in this
489	manuscript is available at <a href="https://github.com/dsarov/P_aeruginosa_ARDaP_manuscript">https://github.com/dsarov/P_aeruginosa_ARDaP_manuscript</a> .
490	<b>Competing interests.</b> The authors declare that they have no competing interests.
491	Funding. This work was supported by Advance Queensland [AQIRF0362018 to D.S.S., AQRF13016-
492	17RD2 to E.P.P.]; the Wishlist Sunshine Coast Health Foundation [2019-14 to T.B., E.P.P., D.S.S.]; and
493	the National Health and Medical Research Council [GNT455919 to S.C.B.]. The funders had no role in
494	study design, data acquisition, analysis, interpretation, writing, or manuscript submission.
495	Authors' contributions. DEM drafted the initial manuscript, compiled the original <i>P. aeruginosa</i> AMR
496	variant database, performed data analyses and laboratory work, and assisted with ARDaP software
497	refinement; TB provided chronic obstructive pulmonary disease respiratory specimens that were used
498	to retrieve <i>P. aeruginosa</i> isolates, assisted with obtaining ethics approvals for sputum and bronchial

499 washing collection, and obtained study funding; SCB provided CF sputa that were used to retrieve P. 500 aeruginosa isolates, and obtained ethics approval for sputum collection; KM provided bloodstream P. 501 aeruginosa isolates, and obtained ethics approval for blood collection; EPP assisted with study 502 conception, obtaining and overseeing ethics approvals, manuscript preparation, data analyses and 503 laboratory work, provided student supervision, obtained study funding, and assisted with curation of 504 the natural variant database; and DSS conceived and led the study, wrote the ARDaP software, refined 505 the P. aeruginosa AMR variant database, assisted with manuscript preparation, data analyses and 506 laboratory work, provided student supervision, and obtained study funding. All authors read and 507 approved of the final manuscript.

- 508 Acknowledgements. We wish to thank Jane Neill (Sunshine Coast Hospital and Health Service,
- 509 Sunshine Coast University Hospital) for providing the chronic obstructive pulmonary samples used in

510 this study, and Kay Ramsay (University of Queensland) and Tamieka Fraser (University of the Sunshine

511 Coast) for laboratory support.

### 512 References

513 1. Mancuso G, Midiri A, Gerace E, Biondo C: Bacterial antibiotic resistance: The most critical 514 pathogens. Pathogens (Basel, Switzerland) 2021, 10(10):1310. 515 2. Bassetti M, Merelli M, Temperoni C, Astilean A: New antibiotics for bad bugs: where are we? 516 Annals of Clinical Microbiology and Antimicrobials 2013, 12(1):22. 517 3. Alanis AJ: Resistance to antibiotics: are we in the post-antibiotic era? Archives of Medical 518 Research 2005, 36(6):697-705. 519 4. Antimicrobial resistance: Tackling a crisis for the health and wealth of nations 520 5. G. B. D. Antimicrobial Resistance Collaborators: Global mortality associated with 33 bacterial 521 pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 522 2022, 400(10369):2221-2248. 523 6. Denissen J, Reyneke B, Waso-Reyneke M, Havenga B, Barnard T, Khan S, Khan W: Prevalence 524 of ESKAPE pathogens in the environment: Antibiotic resistance status, community-acquired 525 infection and risk to human health. Int J Hyg Environ Health 2022, **244**:114006. 526 7. Haenni M, Hocquet D, Ponsin C, Cholley P, Guyeux C, Madec JY, Bertrand X: Population 527 structure and antimicrobial susceptibility of Pseudomonas aeruginosa from animal 528 infections in France. BMC Vet Res 2015, 11:9. 529 8. Mahfouz N, Ferreira I, Beisken S, von Haeseler A, Posch AE: Large-scale assessment of 530 antimicrobial resistance marker databases for genetic phenotype prediction: a systematic 531 review. Journal of Antimicrobial Chemotherapy 2020, 75(11):3099-3108. 532 9. Khaledi A, Weimann A, Schniederjans M, Asgari E, Kuo TH, Oliver A, Cabot G, Kola A, Gastmeier 533 P, Hogardt M et al: Predicting antimicrobial resistance in Pseudomonas aeruginosa with 534 machine learning-enabled molecular diagnostics. EMBO Mol Med 2020, 12(3):e10264. 535 10. Bortolaia V, Kaas RS, Ruppe E, Roberts MC, Schwarz S, Cattoir V, Philippon A, Allesoe RL, Rebelo AR, Florensa AF et al: ResFinder 4.0 for predictions of phenotypes from genotypes. 536 537 Journal of Antimicrobial Chemotherapy 2020, 75(12):3491-3500. 538 11. Alcock BP, Raphenya AR, Lau TTY, Tsang KK, Bouchard M, Edalatmand A, Huynh W, Nguyen A-539 LV, Cheng AA, Liu S et al: CARD 2020: antibiotic resistome surveillance with the 540 comprehensive antibiotic resistance database. Nucleic Acids Research 2019, 48(D1):D517-541 D525. 542 12. Hunt M, Mather AE, Sanchez-Buso L, Page AJ, Parkhill J, Keane JA, Harris SR: ARIBA: Rapid 543 antimicrobial resistance genotyping directly from sequencing reads. Microbial genomics 544 2017, **3**(10):e000131. 545 13. Zankari E, Allesoe R, Joensen KG, Cavaco LM, Lund O, Aarestrup FM: PointFinder: A novel web 546 tool for WGS-based detection of antimicrobial resistance associated with chromosomal 547 point mutations in bacterial pathogens. Journal of Antimicrobial Chemotherapy 2017, 548 **72**(10):2764-2768. 549 14. Madden DE, Webb JR, Steinig EJ, Currie BJ, Price EP, Sarovich DS: Taking the next-gen step: 550 Comprehensive antimicrobial resistance detection from Burkholderia pseudomallei. 551 *EBioMedicine* 2021, **63**:103152. 552 15. Lister PD, Wolter DJ, Hanson ND: Antibacterial-resistant Pseudomonas aeruginosa: Clinical 553 impact and complex regulation of chromosomally encoded resistance mechanisms. Clinical 554 Microbiology Reviews 2009, 22(4):582-610. 555 16. Pesesky MW, Hussain T, Wallace M, Patel S, Andleeb S, Burnham CD, Dantas G: Evaluation of 556 machine learning and rules-based approaches for predicting antimicrobial resistance profiles 557 in Gram-negative Bacilli from whole genome sequence data. Frontiers in microbiology 2016, 558 **7**:1887. 559 17. Gupta SK, Padmanabhan BR, Diene SM, Lopez-Rojas R, Kempf M, Landraud L, Rolain JM: ARG-560 ANNOT, a new bioinformatic tool to discover antibiotic resistance genes in bacterial 561 genomes. Antimicrobial agents and chemotherapy 2014, 58(1):212-220.

562	18.	Stover CK, Pham XQ, Erwin AL, Mizoguchi SD, Warrener P, Hickey MJ, Brinkman FS, Hufnagle
563		WO, Kowalik DJ, Lagrou M et al: Complete genome sequence of Pseudomonas aeruginosa
564		PAO1, an opportunistic pathogen. Nature 2000, 406(6799):959-964.
565	19.	Lopez-Causape C, Cabot G, Del Barrio-Tofino E, Oliver A: The versatile mutational resistome of
566		<b>Pseudomonas aeruginosa</b> . Frontiers in microbiology 2018, <b>9</b> :685.
567	20.	Kos VN, Deraspe M, McLaughlin RE, Whiteaker JD, Roy PH, Alm RA, Corbeil J, Gardner H: The
568		resistome of <i>Pseudomonas aeruainosa</i> in relationship to phenotypic susceptibility
569		Antimicrobial agents and chemotherapy 2015. <b>59</b> (1):427-436.
570	21	Poole K' <b>Pseudomonas geruginosa: Resistance to the max</b> Frontiers in microbiology 2011
570	~ .	<b>2</b> :65-65
572	22	Richardot C Plesiat P Fournier D Monlezun I Broutin I Hanes C <b>Carbanenem resistance in</b>
572	22.	cystic fibrosis strains of <i>Pseudomonas aeruginosa</i> as a result of amino acid substitutions in
573		porin Opro International journal of antimicrobial agents 2015 45(5):529 532
574	22	Tomác M. Doumith M. Warner M. Turten JE. Beceire A. Bou G. Livermere DM. Woodford N:
575	25.	Efflux numes OneD novin AmpC hate lastemase, and multirecistenes in Broudomanas
570		Entux pumps, Opro point, Ampe beta-lactamase, and multiresistance in <i>Pseudomonus</i>
5//		aeruginosa isolates from cystic fibrosis patients. Antimicrobial agents and chemotherapy
5/8	~ .	2010, <b>54</b> (5):2219-2224.
5/9	24.	Lister PD, Wolter DJ, Hanson ND: Antibacterial-resistant Pseudomonas aeruginosa: Clinical
580		impact and complex regulation of chromosomally encoded resistance mechanisms. Clinical
581		Microbiology Reviews 2009, <b>22</b> (4):582-610.
582	25.	Bortolaia V, Kaas RS, Ruppe E, Roberts MC, Schwarz S, Cattoir V, Philippon A, Allesoe RL,
583		Rebelo AR, Florensa AF et al: ResFinder 4.0 for predictions of phenotypes from genotypes. J
584		Antimicrob Chemother 2020, <b>75</b> (12):3491-3500.
585	26.	Heffernan AJ, Sime FB, Sarovich DS, Neely M, Guerra-Valero Y, Naicker S, Cottrell K, Harris P,
586		Andrews KT, Ellwood D et al: Pharmacodynamic evaluation of plasma and epithelial lining
587		fluid exposures of amikacin against <i>Pseudomonas aeruginosa</i> in a dynamic <i>in vitro</i> hollow-
588		fiber infection model. Antimicrobial agents and chemotherapy 2020, 64(9).
589	27.	Lau CH, Krahn T, Gilmour C, Mullen E, Poole K: AmgRS-mediated envelope stress-inducible
590		expression of the mexXY multidrug efflux operon of Pseudomonas aeruginosa.
591		MicrobiologyOpen 2015, <b>4</b> (1):121-135.
592	28.	Bolard A, Plésiat P, Jeannot K: Mutations in gene fusA1 as a novel mechanism of
593		aminoglycoside resistance in clinical strains of Pseudomonas aeruginosa. Antimicrobial
594		agents and chemotherapy 2018, <b>62</b> (2).
595	29.	Wardell SJT, Rehman A, Martin LW, Winstanley C, Patrick WM, Lamont IL: A large-scale whole-
596		genome comparison shows that experimental evolution in response to antibiotics predicts
597		changes in naturally evolved clinical <i>Pseudomonas aeruginosa</i> . Antimicrobial agents and
598		chemotherapy 2019.
599	30.	López-Causapé C. Sommer LM. Cabot G. Rubio R. Ocampo-Sosa AA. Johansen HK. Figuerola J.
600		Cantón R. Kidd TJ. Molin S et al: Evolution of the Pseudomonas aeruainosa mutational
601		resistome in an international cystic fibrosis clone. Sci Rep 2017. 7(1):5555.
602	31	Lopez-Causape C. Rubio R. Cabot G. Oliver A <sup>.</sup> <b>Evolution of the <i>Pseudomonas geruginosg</i></b>
603	01	aminoglycoside mutational resistome in vitro and in the cystic fibrosis setting Antimicrobial
604		agents and chemotherany 2018 62(4)
605	32	Sherrard II Tai AS Wee BA Ramsay KA Kidd TI Ben Zakour NI Whiley DM Beatson SA Bell
606	52.	SC: Within-bost whole genome analysis of an antibiotic resistant <i>Pseudomonas geruginosa</i>
607		strain sub-type in cystic fibrosis $P(\alpha S, \Omega) = 2017$ <b>12</b> (3):e0172179
609	22	Fong V. Jonkor MI. Moustakas I. Brul S. Tor Kuilo PH: Dynamics of mutations during
600	55.	development of resistance by <i>Braudomenas garuginesa</i> against five antibiotics
009		Artimiarabiel generate and charactheurous 2016 60/7):4000 4226
01U 611	24	Antimicrovial agents and chemiotherapy 2010, <b>00</b> (7):4229-4230. Khaladi A. Maimann A. Sahniadariana M. Agari E. Kwa T.H. Olivar A. Cahat C. Kala A.
612 612	54.	Knaleur A, Weimann A, Schnieuerjans W, Asgan E, Kuo T-H, Uliver A, Cabot G, Kola A,
б12 С12		Gastmerer P, Hogardt IVI et al. Predicting antimicrobial resistance in Pseudomonas
<u>613</u>		aeruginosa with machine learning-enabled molecular diagnostics. EMBO molecular medicine
614		2020, <b>12</b> (3):e10264-e10264.

615	35.	Sanz-Garcia F, Hernando-Amado S, Martinez JL: Mutational evolution of Pseudomonas
616		aeruginosa resistance to ribosome-targeting antibiotics. Front Genet 2018, 9:451.
617	36.	Schurek KN, Marr AK, Taylor PK, Wiegand I, Semenec L, Khaira BK, Hancock RE: Novel genetic
618		determinants of low-level aminoglycoside resistance in <i>Pseudomonas aeruginosa</i> .
619		Antimicrobial agents and chemotherapy 2008, <b>52</b> (12):4213-4219.
620	37.	Sun E, Gill EE, Falsafi R, Yeung A, Liu S, Hancock REW: Broad-spectrum adaptive antibiotic
621		resistance associated with <i>Pseudomonas aeruginosa</i> mucin-dependent surfing motility.
622		Antimicrobial agents and chemotherapy 2018. <b>62</b> (9).
623	38.	Dotsch A. Becker T. Pommerenke C. Magnowska 7. Jansch I. Haussler S: <b>Genomewide</b>
624		identification of genetic determinants of antimicrobial drug resistance in <i>Pseudomongs</i>
625		aeruginosa Antimicropial agents and chemotherapy 2009 <b>53</b> (6):2522-2531
626	39	Berrazeg M. Jeannot K. Ntsogo Enguene VV. Broutin L. Loeffert S. Fournier D. Plesiat P.
627	33.	Mutations in beta-lactamase amnC increase resistance of <i>Pseudomonas geruginosa</i> isolates
628		to antinseudomonal central concrises. Antimicrobial agents and chemotherapy 2015
620		
630	40	Colque CA Albarracín Orio AG Feliziani S Marvig RI Tobares AR Johansen HK Molin S
621	40.	Smania AM: Hypermutator Braudomonas geruginosa evaloits multiple genetic pathways to
622		develop multidrug registones during long term infections in the sirways of sustia fibrasic
622		netions Antimicrohigi gagente and chemotherany 2020, 64(5)
633	41	patients. Antimicrobial agents and chemotherapy 2020, <b>04</b> (5).
034 C2E	41.	Stater CL, Winogrouzki J, Frane-Ribot PA, Oliver A, Knajenpour W, Mark BL: Adding Insult to
635		injury: Mechanistic basis for now Ampe initiations and we set addition and the set of th
636		accelerate cephalosporin hydrolysis and evade avibactam. Antimicrobial agents and
637	42	chemotherapy 2020, <b>64</b> (9).
638	42.	Fernandez-Esgueva M, Lopez-Calleja Al, Mulet X, Fraile-Ribot PA, Cabot G, Huarte R, Rezusta A,
639		Oliver A: Characterization of AmpC beta-lactamase mutations of extensively drug-resistant
640		Pseudomonds deruginosa isolates that develop resistance to cettolozane/tazobactam during
641		therapy. Enferm Infect Microbiol Clin (Engl Ed) 2020, 38(10):474-478.
642	43.	Moya B, Dotsch A, Juan C, Blazquez J, Zamorano L, Haussier S, Oliver A: Beta-lactam resistance
643		response triggered by inactivation of a nonessential penicillin-binding protein. PLos Pathog
644		2009, <b>5</b> (3):e1000353.
645	44.	Zamorano L, Reeve TM, Deng L, Juan C, Moya B, Cabot G, Vocadio DJ, Mark BL, Oliver A: <b>Nagz</b>
646		inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4
647		<b>mutations, in <i>Pseudomonas deruginosa</i></b> . Antimicrobial agents and chemotherapy 2010,
648	45	54(9):3557-3563.
649	45.	Barbosa C, Gregg KS, Woods RJ: Variants in <i>ampb</i> and <i>dacb</i> lead to in vivo resistance
650		evolution of Pseudomonas deruginosa within the central nervous system. Journal of
651		Antimicrobial Chemotherapy 2020, <b>75</b> (11):3405-3408.
652	46.	Langaee TY, Gagnon L, Huletsky A: Inactivation of the ampD gene in Pseudomonas
653		aeruginosa leads to moderate-basal-level and hyperinducible AmpC beta-lactamase
654		expression. Antimicrobial agents and chemotherapy 2000, <b>44</b> (3):583-589.
655	47.	Juan C, Macia MD, Gutierrez O, Vidal C, Perez JL, Oliver A: Molecular mechanisms of beta-
656		lactam resistance mediated by AmpC hyperproduction in <i>Pseudomonas aeruginosa</i> clinical
657		<b>strains</b> . Antimicrobial agents and chemotherapy 2005, <b>49</b> (11):4733-4738.
658	48.	Bagge N, Ciofu O, Hentzer M, Campbell JI, Givskov M, Hoiby N: Constitutive high expression of
659		chromosomal beta-lactamase in <i>Pseudomonas aeruginosa</i> caused by a new insertion
660		sequence (IS1669) located in ampD. Antimicrobial agents and chemotherapy 2002,
661		<b>46</b> (11):3406-3411.
662	49.	Quale J, Bratu S, Gupta J, Landman D: Interplay of efflux system, ampC, and oprD expression
663		in carbapenem resistance of <i>Pseudomonas aeruginosa</i> clinical isolates. Antimicrobial agents
664		and chemotherapy 2006, <b>50</b> (5):1633-1641.
665	50.	Tsutsumi Y, Tomita H, Tanimoto K: Identification of novel genes responsible for
666		overexpression of ampC in Pseudomonas aeruginosa PAO1. Antimicrobial agents and
667		chemotherapy 2013, <b>57</b> (12):5987-5993.

668	51.	Kong KF, Aguila A, Schneper L, Mathee K: <b>Pseudomonas aeruginosa β-lactamase induction</b>
669		requires two permeases, AmpG and AmpP. BMC microbiology 2010, 10:328.
670	52.	Cabot G, Lopez-Causape C, Ocampo-Sosa AA, Sommer LM, Dominguez MA, Zamorano L, Juan
671		C, Tubau F, Rodriguez C, Moya B et al: Deciphering the resistome of the widespread
672		Pseudomonas aeruginosa sequence type 175 international high-risk clone through whole-
673		genome sequencing. Antimicrob Agents Chemother 2016, 60(12):7415-7423.
674	53.	Clark ST, Sinha U, Zhang Y, Wang PW, Donaldson SL, Coburn B, Waters VJ, Yau YCW, Tullis DE,
675		Guttman DS et al: Penicillin-binding protein 3 is a common adaptive target among
676		Pseudomonas aeruginosa isolates from adult cystic fibrosis patients treated with beta-
677		lactams. International journal of antimicrobial agents 2019, 53(5):620-628.
678	54.	Del Barrio-Tofiño E, López-Causapé C, Cabot G, Rivera A, Benito N, Segura C, Montero MM,
679		Sorlí L, Tubau F, Gómez-Zorrilla S et al: Genomics and susceptibility profiles of extensively
680		drug-resistant Pseudomonas aeruginosa isolates from Spain. Antimicrobial agents and
681		chemotherapy 2017, <b>61</b> (11).
682	55.	Sherrard LJ, Wee BA, Duplancic C, Ramsay KA, Dave KA, Ballard E, Wainwright CE, Grimwood K,
683		Sidjabat HE, Whiley DM et al: Emergence and impact of oprD mutations in Pseudomonas
684		aeruginosa strains in cystic fibrosis. Journal of cystic fibrosis : official journal of the European
685		Cystic Fibrosis Society 2021.
686	56.	Livermore DM: Interplay of impermeability and chromosomal beta-lactamase activity in
687		imipenem-resistant Pseudomonas aeruginosa. Antimicrobial agents and chemotherapy 1992,
688		<b>36</b> (9):2046-2048.
689	57.	Ocampo-Sosa AA, Cabot G, Rodriguez C, Roman E, Tubau F, Macia MD, Moya B, Zamorano L,
690		Suarez C, Pena C et al: Alterations of OprD in carbapenem-intermediate and -susceptible
691		strains of <i>Pseudomonas aeruginosa</i> isolated from patients with bacteremia in a Spanish
692		multicenter study. Antimicrobial agents and chemotherapy 2012, 56(4):1703-1713.
693	58.	Fraile-Ribot PA, Mulet X, Cabot G, Del Barrio-Tofino E, Juan C, Perez JL, Oliver A: In vivo
694		emergence of resistance to novel cephalosporin-beta-lactamase inhibitor combinations
695		through the duplication of amino acid D149 from OXA-2 beta-lactamase (OXA-539) in
696		sequence type 235 Pseudomonas aeruginosa. Antimicrobial agents and chemotherapy 2017,
697		<b>61</b> (9).
698	59.	Cabot G, Bruchmann S, Mulet X, Zamorano L, Moyà B, Juan C, Haussler S, Oliver A:
699		Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple
700		mutations leading to overexpression and structural modification of AmpC. Antimicrobial
701		agents and chemotherapy 2014, <b>58</b> (6):3091-3099.
702	60.	Perron K, Caille O, Rossier C, Van Delden C, Dumas JL, Kohler T: CzcR-CzcS, a two-component
703		system involved in heavy metal and carbapenem resistance in <i>Pseudomonas aeruginosa</i> . J
704		Biol Chem 2004, <b>279</b> (10):8761-8768.
705	61.	Higgins PG, Fluit AC, Milatovic D, Verhoef J, Schmitz FJ: Mutations in GyrA, ParC, MexR and
706		NfxB in clinical isolates of Pseudomonas aeruginosa. International journal of antimicrobial
707		agents 2003, <b>21</b> (5):409-413.
708	62.	Lee JK, Lee YS, Park YK, Kim BS: Alterations in the GyrA and GyrB subunits of topoisomerase II
709		and the ParC and ParE subunits of topoisomerase IV in ciprofloxacin-resistant clinical
710		isolates of Pseudomonas aeruginosa. International journal of antimicrobial agents 2005,
711		<b>25</b> (4):290-295.
712	63.	Bruchmann S, Dötsch A, Nouri B, Chaberny IF, Häussler S: Quantitative contributions of target
713		alteration and decreased drug accumulation to Pseudomonas aeruginosa fluoroquinolone
714		resistance. Antimicrobial agents and chemotherapy 2013, 57(3):1361-1368.
715	64.	Jalal S, Wretlind B: Mechanisms of quinolone resistance in clinical strains of Pseudomonas
716		aeruginosa. Microbial drug resistance (Larchmont, NY) 1998, <b>4</b> (4):257-261.
717	65.	Alyaseen SA, Piper KE, Rouse MS, Steckelberg JM, Patel R: Selection of cross-resistance
718		following exposure of <i>Pseudomonas aeruginosa</i> clinical isolates to ciprofloxacin or cefepime.
719		Antimicrobial agents and chemotherapy 2005, <b>49</b> (6):2543-2545.

720	66.	Akasaka T, Tanaka M, Yamaguchi A, Sato K: <b>Type II topoisomerase mutations in</b>
721		fluoroquinolone-resistant clinical strains of <i>Pseudomonas aeruginosa</i> isolated in 1998 and
722		1999: role of target enzyme in mechanism of fluoroquinolone resistance. Antimicrobial
723		agents and chemotherapy 2001, <b>45</b> (8):2263-2268.
724	67.	Rehman A, Jeukens J, Levesque RC, Lamont IL: Gene-gene interactions dictate ciprofloxacin
725		resistance in Pseudomonas aeruginosa and facilitate prediction of resistance phenotype
726		from genome sequence data. Antimicrobial agents and chemotherapy 2021, 65(7):e0269620.
727	68.	Chilam J, Argimon S, Limas MT, Masim ML, Gayeta JM, Lagrada ML, Olorosa AM, Cohen V,
728		Hernandez LT, Jeffrey B <i>et al</i> : Genomic surveillance of <i>Pseudomonas aeruginosa</i> in the
729		Philippines, 2013-2014. Western Pac Surveill Response J 2021, 12(2):4-18.
730	69.	Lee JY, Ko KS: Mutations and expression of PmrAB and PhoPQ related with colistin resistance
731		in Pseudomonas aeruginosa clinical isolates. Diagn Microbiol Infect Dis 2014, 78(3):271-276.
732	70.	Moskowitz SM, Ernst RK, Miller SI: PmrAB, a two-component regulatory system of
733		Pseudomonas aeruginosa that modulates resistance to cationic antimicrobial peptides and
734		addition of aminoarabinose to lipid A. J Bacteriol 2004, 186(2):575-579.
735	71.	Abraham N, Kwon DH: A single amino acid substitution in PmrB is associated with polymyxin
736		B resistance in clinical isolate of Pseudomonas aeruginosa. FEMS Microbiol Lett 2009,
737		<b>298</b> (2):249-254.
738	72.	Moskowitz SM, Brannon MK, Dasgupta N, Pier M, Sgambati N, Miller AK, Selgrade SE, Miller SI,
739		Denton M, Conway SP et al: PmrB mutations promote polymyxin resistance of Pseudomonas
740		aeruginosa isolated from colistin-treated cystic fibrosis patients. Antimicrobial agents and
741		chemotherapy 2012, <b>56</b> (2):1019-1030.
742	73.	Owusu-Anim D, Kwon DH: Differential role of two-component regulatory systems (phoPQ
743		and pmrAB) in polymyxin B susceptibility of Pseudomonas aeruginosa. Advances in
744		microbiology 2012, <b>2</b> (1).
745	74.	Choi MJ, Ko KS: Mutant prevention concentrations of colistin for Acinetobacter baumannii,
746		Pseudomonas aeruginosa and Klebsiella pneumoniae clinical isolates. Journal of
747		Antimicrobial Chemotherapy 2014, <b>69</b> (1):275-277.
748	75.	Saito K, Akama H, Yoshihara E, Nakae T: Mutations affecting DNA-binding activity of the
749		MexR repressor of mexR-mexA-mexB-oprM operon expression. J Bacteriol 2003,
750		<b>185</b> (20):6195-6198.
751	76.	Vaez H, Safaei HG, Faghri J: The emergence of multidrug-resistant clone ST664 Pseudomonas
752		aeruginosa in a referral burn hospital, Isfahan, Iran. Burns Trauma 2017, 5:27.
753	77.	Braz VS, Furlan JP, Fernandes AF, Stehling EG: Mutations in NalC induce MexAB-OprM
754		overexpression resulting in high level of aztreonam resistance in environmental isolates of
755		Pseudomonas aeruginosa. FEMS Microbiol Lett 2016, 363(16).
756	78.	Suresh M, Nithya N, Jayasree PR, Vimal KP, Manish Kumar PR: Mutational analyses of
757		regulatory genes, <i>mexR</i> , <i>nalC</i> , <i>nalD</i> and <i>mexZ</i> of <i>mexAB-oprM</i> and <i>mexX</i> Y operons, in efflux
758		pump hyperexpressing multidrug-resistant clinical isolates of <i>Pseudomonas aeruginosa</i> .
759		World journal of microbiology & biotechnology 2018, <b>34</b> (6):83.
760	79.	Yan J, Estanbouli H, Liao C, Kim W, Monk JM, Rahman R, Kamboj M, Palsson BO, Qiu W, Xavier
761		JB: Systems-level analysis of NalD mutation, a recurrent driver of rapid drug resistance in
762		acute Pseudomonas aeruginosa infection. PLoS Comput Biol 2019, 15(12):e1007562.
763	80.	Sobel ML, Neshat S, Poole K: Mutations in PA2491 (mexS) promote MexT-dependent mexEF-
764		oprN expression and multidrug resistance in a clinical strain of Pseudomonas aeruginosa. J
765		Bacteriol 2005, <b>187</b> (4):1246-1253.
766	81.	Juarez P, Broutin I, Bordi C, Plésiat P, Llanes C: Constitutive activation of mexT by amino acid
767		substitutions results in MexEF-OprN overproduction in clinical isolates of <i>Pseudomonas</i>
768		<b>aeruginosa</b> . Antimicrobial agents and chemotherapy 2018, <b>62</b> (5).
769	82.	Llanes C, Köhler T, Patry I, Dehecq B, van Delden C, Plésiat P: Role of the MexEF-OprN efflux
770		system in low-level resistance of Pseudomonas aeruginosa to ciprofloxacin. Antimicrobial
771		agents and chemotherapy 2011, <b>55</b> (12):5676-5684.

772	83.	Guénard S, Muller C, Monlezun L, Benas P, Broutin I, Jeannot K, Plésiat P: Multiple mutations
773		lead to MexXY-OprM-dependent aminoglycoside resistance in clinical strains of
774		<b>Pseudomonas aeruginosa</b> . Antimicrobial agents and chemotherapy 2014, <b>58</b> (1):221-228.
775	84.	Chuanchuen R, Wannaprasat W, Ajariyakhajorn K, Schweizer HP: Role of the MexXY multidrug
776		efflux pump in moderate aminoglycoside resistance in <i>Pseudomonas aeruginosa</i> isolates
777		from Pseudomonas mastitis. Microbiology and immunology 2008, 52(8):392-398.
778	85.	Hocquet D, Muller A, Blanc K, Plesiat P, Talon D, Monnet DL, Bertrand X: Relationship
779		between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates
780		of Pseudomonas aeruainosa. Antimicropial agents and chemotherapy 2008 52(3):1173-1175
781	86.	Islam S. Jalal S. Wretlind B: Expression of the MexXY efflux pump in amikacin-resistant
782		isolates of Pseudomonas aeruainosa. Clinical microbioloay and infection the official
783		publication of the European Society of Clinical Microbiology and Infectious Diseases 2004
784		<b>10</b> (10):877-883
785	87	Alvarez-Ortega C Wiegand L Olivares L Hancock RE Martinez II : The intrinsic resistome of
786	07.	Pseudomonas aeruainosa to beta-lactams Virulence 2011 <b>2</b> (2):144-146
787	88	Li X7 Ma D. Livermore DM. Nikaido H: <b>Pole of efflux numn(s) in intrinsic resistance of</b>
707	00.	Breudomongs geruginosa: active offlux as a contributing factor to bota lastam resistance of
700		Antimicrobial agants and chamatharany 1004 20/2):1742 1752
705	<u>00</u>	Antimicrobial agents and chemotherapy 1334, 36(6),1742-1732.
790	09.	Poole K, Heimich's DE, Neshat S. Cloning and sequence analysis of an Enved homologue in
791		the siderenhore proverding. Mel Misrobiol 1002, 10/2)/E20 E44
792	00	the siderophore pyoveraine. <i>Wol Wicrobiol</i> 1993, <b>10</b> (3):529-544.
793	90.	Wine I, Morita Y, Kataoka A, Mizushima I, Isuchiya I: Expression in Escherichia coli of a new
794		multidrug efflux pump, MexXY, from Pseudomonds deruginosa. Antimicrobial agents and
795	0.1	chemotherapy 1999, <b>43</b> (2):415-417.
/96	91.	Poole K, Gotoh N, Tsujimoto H, Zhao Q, Wada A, Yamasaki T, Neshat S, Yamagishi J, Li XZ,
/9/		Nishino I: Overexpression of the mexC-mexD-oprJ efflux operon in nfxB-type multidrug-
/98		resistant strains of Pseudomonas aeruginosa. Mol Microbiol 1996, 21(4):/13-/24.
799	92.	Köhler I, Michéa-Hamzehpour M, Henze U, Gotoh N, Curty LK, Pechère JC: Characterization of
800		MexE-MexF-OprN, a positively regulated multidrug efflux system of <i>Pseudomonas</i>
801		<b>aeruginosa</b> . Mol Microbiol 1997, <b>23</b> (2):345-354.
802	93.	Anuj SN, Whiley DM, Kidd TJ, Bell SC, Wainwright CE, Nissen MD, Sloots TP: Identification of
803		<i>Pseudomonas aeruginosa</i> by a duplex real-time polymerase chain reaction assay targeting
804		the ecfX and the gyrB genes. Diagn Microbiol Infect Dis 2009, 63(2):127-131.
805	94.	Oliver A, Baquero F, Blázquez J: <b>The mismatch repair system (<i>mutS, mutL</i> and <i>uvrD</i> genes) in</b>
806		Pseudomonas aeruginosa: molecular characterization of naturally occurring mutants. Mol
807		Microbiol 2002, <b>43</b> (6):1641-1650.
808	95.	van Belkum A, Soriaga LB, LaFave MC, Akella S, Veyrieras JB, Barbu EM, Shortridge D, Blanc B,
809		Hannum G, Zambardi G et al: Phylogenetic distribution of CRISPR-Cas systems in antibiotic-
810		resistant Pseudomonas aeruginosa. mBio 2015, 6(6):e01796-01715.
811	96.	Buhl M, Kästle C, Geyer A, Autenrieth IB, Peter S, Willmann M: Molecular evolution of
812		extensively drug-resistant (XDR) Pseudomonas aeruginosa strains from patients and hospital
813		environment in a prolonged outbreak. Frontiers in microbiology 2019, 10:1742.
814	97.	Cabot G, López-Causapé C, Ocampo-Sosa AA, Sommer LM, Domínguez MA, Zamorano L, Juan
815		C, Tubau F, Rodríguez C, Moyà B et al: Deciphering the resistome of the widespread
816		Pseudomonas aeruginosa Sequence Type 175 international high-risk clone through whole-
817		genome sequencing. Antimicrobial agents and chemotherapy 2016, 60(12):7415-7423.
818	98.	CDC & FDA Antibiotic Resistance Isolate Bank for Pseudomonas aeruginosa [Available at:
819		https://wwwn.cdc.gov/ARIsolateBank/Panel/PanelDetail?ID=12]
820	99.	Ramanathan B, Jindal HM, Le CF, Gudimella R, Anwar A, Razali R, Poole-Johnson J, Manikam R,
821		Sekaran SD: Next generation sequencing reveals the antibiotic resistant variants in the
822		genome of <i>Pseudomonas aeruginosa</i> . <i>PLoS One</i> 2017, <b>12</b> (8):e0182524.

823	100.	Tsang KK, Maguire F, Zubyk HL, Chou S, Edalatmand A, Wright GD, Beiko RG, McArthur AG:
824		Identifying novel β-lactamase substrate activity through <i>in silico</i> prediction of antimicrobial
825		resistance. Microbial genomics 2021, 7(1).
826	101.	Wardell SJT, Rehman A, Martin LW, Winstanley C, Patrick WM, Lamont IL: A large-scale whole-
827		genome comparison shows that experimental evolution in response to antibiotics predicts
828		changes in naturally evolved clinical <i>Pseudomonas geruginosa</i> . Antimicrobial agents and
829		chemotherapy 2019 <b>63</b> (12)
830	102	Cortes-Lara S. Barrio-Tofiño ED. Lónez-Causané C. Oliver A. Gemara-Seimc Reini Pseudomonas
831		study Group: Predicting Pseudomonas geruginosa suscentibility phenotypes from whole
832		genome sequence resistome analysis. Clinical microbiology and infection : the official
833		publication of the European Society of Clinical Microbiology and Infectious Diseases 2021
831		<b>27</b> /11)·1631_1637
034 025	102	Sup 7 Vang E. Ji I. Cao W. Liu C. Ding P. Yu V: Dissecting the genotypic features of a
000	105.	Sun Z, Hang F, Ji J, Cao W, Liu C, Ding B, Xu X. Dissecting the genotypic reatures of a
020		in Shanghai. China Miarahiri gangming 2022, 0(4)
857	104	In Snangnal, China. Microbial genomics 2023, 9(4).
838	104.	SU M, Satola SW, Read TD: Genome-based prediction of bacterial antibiotic resistance.
839		Journal of clinical microbiology 2019, <b>57</b> (3):e01405-01418.
840	105.	Madden DE, McCarthy KL, Bell SC, Olagoke O, Baird T, Neill J, Ramsay KA, Kidd TJ, Stewart AG,
841		Subedi S et al: Rapid fluoroquinolone resistance detection in Pseudomonas aeruginosa using
842		mismatch amplification mutation assay-based real-time PCR. J Med Microbiol 2022,
843		<b>71</b> (10):001593.
844	106.	Madden DE, Olagoke O, Baird T, Neill J, Ramsay KA, Fraser TA, Bell SC, Sarovich DS, Price EP:
845		Express yourself: Quantitative real-time PCR assays for rapid chromosomal antimicrobial
846		resistance detection in Pseudomonas aeruginosa. Antimicrobial agents and chemotherapy
847		2022, <b>66</b> (5):e0020422.
848	107.	Mobegi FM, Cremers AJ, de Jonge MI, Bentley SD, van Hijum SA, Zomer A: Deciphering the
849		distance to antibiotic resistance for the pneumococcus using genome sequencing data. Sci
850		Rep 2017, <b>7</b> :42808.
851	108.	Sarovich DS, Price EP: SPANDx: a genomics pipeline for comparative analysis of large haploid
852		whole genome re-sequencing datasets. BMC research notes 2014, 7:618.
853	109.	Crouch DJM, Bodmer WF: Polygenic inheritance, GWAS, polygenic risk scores, and the search
854		for functional variants. Proc Natl Acad Sci U S A 2020, <b>117</b> (32):18924-18933.
855	110.	ARDaP - Antimicrobial Resistance Detection and Prediction.
856		[https://github.com/dsarov/ARDaP]
857	111.	Sherry NL, Horan KA, Ballard SA, Gonıalves da Silva A, Gorrie CL, Schultz MB, Stevens K,
858		Valcanis M, Sait ML, Stinear TP et al: An ISO-certified genomics workflow for identification
859		and surveillance of antimicrobial resistance. Nat Commun 2023, 14(1):60.
860	112.	Feldgarden M, Brover V, Haft DH, Prasad AB, Slotta DJ, Tolstoy I, Tyson GH, Zhao S, Hsu CH,
861		McDermott PF et al: Validating the AMRFinder tool and resistance gene database by using
862		antimicrobial resistance genotype-phenotype correlations in a collection of isolates.
863		Antimicrobial agents and chemotherapy 2019. <b>63</b> (11):e00483-00419.
864	113	Bekkar M. Diemaa HK. Alitouche TA: <b>Evaluation measures for models assessment over</b>
865		imbalanced data sets //nfEng Ann/2013 3(10):27-38
866	114	Hicks AL Wheeler N Sanchez-Ruso L Rakeman II. Harris SR Grad VH: <b>Evaluation of</b>
867	<b>11</b> 7.	narameters affecting performance and reliability of machine learning-based antibiotic
868		suscentibility testing from whole genome sequencing data. PLoS Comput Rial 2019
860		15/0):01007340
809 870	115	Van Goethom N. Descamps T. Devleesschauwer B. Beesens NHC. Been NAM. Van Oven H.
070	11.5.	Pahert A: Status and notantial of bacterial genemics for public health practice a scening
0/1 070		review Implement Sci 2010, 14/1):70
0/2 070	116	ICVICW. IIII/IEIIICOL 2013, 14(1)./3. Kidd TL Ditchia SB. Damcay KA. Grimwaad K. Dall SC. Dainay DD. Draudam ange gangeingen
0/3 071	110.	Nuu 13, Nitchie SK, Kamsay KA, Ommwood K, Bell SC, Kamey PB: <b>Pseudomonas deruginosa</b>
8/4 075		exhibits frequent recombination, but only a limited association between genotype and
٥/٥		ecological setting. PLOS One 2012, 7(9):e44199.

<ul> <li>colistin - evaluation of seven commercial MIC products against standard broth microdilution</li> <li>for Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter</li> <li>spp. Clinical microbiology and infection: the official publication of the European Society of</li> <li>Clinical Microbiology and Infection: Diseases 2018, 24(8):865-870.</li> <li>Bassetti M, Vena A, Croxatto A, Righi E, Guery B: How to manage Pseudomonas aeruginosa</li> <li>infections. Drugs Context 2018, 7:212527.</li> <li>Gurjar M: Colistin for lung infection: an update. J Intensive Care 2015, 3(1):3.</li> <li>Sabuda DM, Laupland K, Pitout J, Dalton B, Rabin H, Loule T, Conly J: Utilization of colistin for</li> <li>treatment of multiding-resistant Pseudomonas aeruginosa. Can J Infect Dis Med Microbiol</li> <li>2008, 19(6):413-418.</li> <li>Li H, Luo YF, Williams BJ, Blackwell TS, Xie CM: Structure and function of OprD protein in</li> <li>Pseudomonas aeruginosa: from antibiotic resistance to novel therapies. Int J Med Microbiol</li> <li>2012, 302(2):63-68.</li> <li>122. Cabot G, Ocampo-Sosa AA, Tubau F, Macia MD, Rodriguez C, Moya B, Zamorano L, Suarez C,</li> <li>Pena C, Matinez-Martinez L et al: Overexpression of AmpC and efflux pumps in</li> <li>Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on</li> <li>resistance in a Spanish multicenter study. Antimicrobial agents and chemotherapy 2011,</li> <li>55(5):1006-1911.</li> <li>Lee JY, Ko KS: OprD mutations and inactivation, expression of efflux pumps and AmpC, and</li> <li>metrantional joural of antimicrobial agents 2012, 40(2):168-172.</li> <li>Lae JY, Ko KS: OprD mutations and inactivation, expression of efflux pumps and AmpC, and</li> <li>metrantolon lowal of antimicrobial agents and chemotherapy 2011,</li> <li>55(5):1006-1911.</li> <li>Lee JY, Ko KS: OprD mutations and inactivation, expression of efflux pumps and AmpC, and<th>876</th><th>117.</th><th>Matuschek E, Ahman J, Webster C, Kahlmeter G: Antimicrobial susceptibility testing of</th></li></ul>	876	117.	Matuschek E, Ahman J, Webster C, Kahlmeter G: Antimicrobial susceptibility testing of
<ul> <li>for Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter</li> <li>spp. Clinical microbiology and infectious Diseases 2018, 24(8):865-870.</li> <li>Bassetti M, Vena A, Croxatto A, Righi E, Guery B: How to manage Pseudomonas aeruginosa</li> <li>infections. Drugs Context 2018, 7:212527.</li> <li>Gurjar M: Collstin for Jung Infection: an update. J Intensive Care 2015, 3(1):3.</li> <li>Sabuda DM, Laupland K, Pitout J, Dalton B, Rabin H, Louie T, Conly J: Utilization of collistin for</li> <li>treatment of multidrug-resistant Pseudomonas aeruginosa. Can J Infect Dis Med Microbiol</li> <li>2008, 19(6):413-418.</li> <li>Li H, Luo YF, Williams BJ, Blackwell TS, Xie CM: Structure and function of OprD protein in</li> <li><i>Pseudomonas aeruginosa</i>: from antibiotic resistance to novel therapies. Int J Med Microbiol</li> <li>2012, 302(2):63-68.</li> <li>Cabot G, Ocampo-Sosa AA, Tubau F, Macia MD, Rodriguez C, Moya B, Zamorano L, Suarez C,</li> <li>Pena C, Martinez-Martinez L et al: Overexpression of AmpC and efflux pumps in</li> <li><i>Pseudomonas aeruginosa</i> isolates from bloodstream infections: prevalence and impact on</li> <li>resistance in a Spanish multicenter study. Antimicrobial agents and chemotherapy 2011,</li> <li>55(5):1906-1911.</li> <li>Lee JY, Ko KS: OprD mutations and inactivation, expression of efflux pumps and AmpC, and</li> <li>metallo-β-lactamases in carbapenem-resistant <i>Pseudomonas aeruginosa</i> isolates from South</li> <li>Korea. International journal of antimicrobial agents 2012, 40(2):168-172.</li> <li>Juan C, Torrens G, González-Nicolau M, Oliver A: Diversity and regulation of intrinsic beta-</li> <li>lactamases from non-fermenting and other Gram-negative opportunistic pathogens. <i>FEMS</i></li> <li>Microbiol Rev 2017, 41(6):781-815.</li> <li>Lew YSB, Bonnie M: Antibacterial resistance orlowalis: causes, challenges and responses.</li> <li>Motorabio Rev 2017, 41(6):781-815.</li></ul>	877		colistin - evaluation of seven commercial MIC products against standard broth microdilution
<ul> <li>spp. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2018, 24(8):865-870.</li> <li>Bassetti M, Vena A, Croxatto A, Righi E, Guery B: How to manage Pseudomonas aeruginosa infections. Drugs Context 2018, 7:212527.</li> <li>Gurjar M: Colistin for lung infection: an update. J Intensive Care 2015, 3(1):3.</li> <li>Sabuda DM, Laupland K, Pitout J, Dalton B, Rabin H, Louie T, Conly J: Utilization of colistin for treatment of multiding-resistant Pseudomonas aeruginosa. Can J Infect Dis Med Microbiol 2008, 19(6):413-418.</li> <li>Li H, Luo YF, Williams BJ, Blackwell TS, Xie CM: Structure and function of OprD protein in Pseudomonas aeruginosa: from antibiotic resistance to novel therapies. Int J Med Microbiol 2012, 302(2):63-68.</li> <li>Cabot G, Ocampo-Sosa AA, Tubau F, Macia MD, Rodriguez C, Moya B, Zamorano L, Suarez C, Pena C, Martinez-Martinez L <i>et al</i>: Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study. Antimicrobial agents and chemotherapy 2011, 55(5):1906-1911.</li> <li>Lee IV, Ko KS: OprD mutations and inactivation, expression of efflux pumps and AmpC, and metallo-β-lactamases in carbapenem-resistant Pseudomonas aeruginosa isolates from South Korea. International journal of antimicrobial agents 2012, 40(2):168-172.</li> <li>Juan C, Torrens G, González-Niccialu M, Oliver A: Diversity and regulation of intrinsic beta- lactamases from non-fermenting and other Gram-negative opportunistic pathogens. FEMS Microbiol Rev 2017, 41(6):781-815.</li> <li>Levy SB, Bonnie M: Antibacterial resistance worldwide: Causes, challenges and responses. Nature Medicine 2004, 10(125):5122-5129.</li> <li>Law COK, Huang C, Pan Q, Lee J, Hao Q, Chan T-F, Lo NWS, Ang IL, Koon A, Ip M et al: A small RNA transforms the multidrug resistance of Pseudomonas aeruginosa to drug susceptibility.</li></ul>	878		for Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter
<ul> <li>Clinical Microbiology and Infectious Diseases 2018, 24(8):865-870.</li> <li>Bassetti M, Vena A, Croxatto A, Righi E, Guery B: How to manage Pseudomonas aeruginosa infections. Drugs Context 2018, 7:212527.</li> <li>Gurjar M: Colistin for lung infection: an update. J Intensive Care 2015, 3(1):3.</li> <li>Sabuda DM, Laupland K, Pitout J, Dalton B, Rabin H, Louie T, Conly J: Utilization of colistin for treatment of multiding-resistant Pseudomonas aeruginosa. Can J Infect Dis Med Microbiol 2008, 19(6):413-418.</li> <li>Li H, Luo YF, Williams BJ, Blackwell TS, Xie CM: Structure and function of OprD protein in Pseudomonas aeruginosa: from antibiotic resistance to novel therapies. Int J Med Microbiol 2012, 302(2):63-68.</li> <li>Cabot G, Ocampo-Sosa AA, Tubau F, Macia MD, Rodriguez C, Moya B, Zamorano L, Suarez C, Pena C, Martinez-Martinez L et al: Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study. Antimicrobial agents and chemotherapy 2011, 55(5):1906-1911.</li> <li>Lee VF, Ko KS: OprD mutations and inactivation, expression of efflux pumps and AmpC, and metallo-β-lactamases in carbapenem-resistant Pseudomonas aeruginosa isolates from South Korea. International journal of antimicrobial agents 2012, 40(2):168-172.</li> <li>Juan C, Torrens G, González-Nicolau M, Oliver A: Diversity and regulation of intrinsic beta- lactamases from non-fermenting and other Gram-negative opportunistic pathogens. <i>FEMS Microbiol Rev</i> 2017, 41(6):781-815.</li> <li>Law COK, Huang C, Pan Q, Lee J, Hao Q, Chan T-F, Lo NWS, Ang IL, Koon A, Ip M et al: A small RNA transforms the multidrug resistance of Pseudomonas aeruginosa ot drug susceptibility. Mol Ther Nucleic Acids 2019, 16:218-228.</li> <li>Law COK, Huang C, Pan Q, Lee J, Hao Q, Chan T-F, Lo NWS, Ang IL, Koon A, Ip M et al: A small RNA transforms the multidrug resistance of Pseudomonas aeruginosa ot drug susceptibility. M</li></ul>	879		<b>spp</b> . Clinical microbiology and infection : the official publication of the European Society of
<ol> <li>118. Bassetti M, Vena A, Croxatto A, Righi E, Guery B: How to manage <i>Pseudomonas aeruginosa</i> infections. Drugs Context 2018, 7:212527.</li> <li>119. Gurjar M: Colisti no fung infection: an update. J Intensive Care 2015, 3(1):3.</li> <li>120. Sabuda DM, Laupland K, Pitout J, Dalton B, Rabin H, Louie T, Conly J: Utilization of colistin for treatment of multidrug-resistant <i>Pseudomonas aeruginosa</i>. Can J Infect Dis Med Microbiol 2008, 19(6):413-418.</li> <li>121. Li H, Luo YF, Williams BJ, Blackwell TS, Xie CM: Structure and function of OprD protein in <i>Pseudomonas aeruginosa</i>: from antibiotic resistance to novel therapies. Int J Med Microbiol 2012, 302(2):63-68.</li> <li>122. Cabot G, Ocampo-Sosa AA, Tubau F, Macia MD, Rodriguez C, Moya B, Zamorano L, Suarez C, Pena C, Martinez-Martinez L <i>et al</i>: Overexpression of <i>AmpC</i> and efflux pumps in <i>Pseudomonas aeruginosa</i> isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study. Antimicrobial agents and chemotherapy 2011, 55(5):1906-1911.</li> <li>123. Lee JY, Ko KS: OprD mutations and inactivation, expression of efflux pumps and AmpC, and metallo-β-lactamases in carbapenem-resistant <i>Pseudomonas aeruginosa</i> isolates from South Korea. International journal of antimicrobial agents 2012, 40(2):168-172.</li> <li>124. Juan C, Torrens G, González-Nicolau M, Oliver A: Diversity and regulation of intrinsic beta- lactamases from non-fermenting and other Gram-negative opportunistic pathogens. <i>FEMS Microbiol Rev</i> 2017, 41(6):781-815.</li> <li>125. Levy SB, Bonnie M: Antibacterial resistance worldwide: Causes, challenges and responses. <i>Nature Medicine</i> 2004, 10(125):S122-S129.</li> <li>126. Law COK, Huang C, Pan Q, Lee J, Hao Q, Chan T-F, Lo NWS, Ang IL, Koon A, Ip M <i>et al</i>: A small RNA transforms the multidrug resistance of <i>Pseudomonas aeruginosa</i> to drug susceptibility. <i>Mol Ther Nucleic Acids</i> 2019, 16:218-228.</li> <li>127. Robicsek A, Strahilevitz J, Jacoby GA, Macielag M, A</li></ol>	880		Clinical Microbiology and Infectious Diseases 2018, <b>24</b> (8):865-870.
<ul> <li>infections. Drugs Context 2018, 7:212527.</li> <li>Gurjar M: Colistin for lung infection: an update. J Intensive Care 2015, 3(1):3.</li> <li>Sabuda DM, Laupland K, Pitout J, Dalton B, Rabin H, Louie T, Conly J: Utilization of colistin for treatment of multidrug-resistant <i>Pseudomonas aeruginosa</i>. Can J Infect Dis Med Microbiol 2008, 19(6):413-418.</li> <li>Li H, Luo YF, Williams BJ, Blackwell TS, Xie CM: Structure and function of OprD protein in <i>Pseudomonas aeruginosa</i>: from antibiotic resistance to novel therapies. Int J Med Microbiol 2012, 302(2):63-68.</li> <li>Cabot G, Ocampo-Sosa AA, Tubau F, Macia MD, Rodriguez C, Moya B, Zamorano L, Suarez C, Pena C, Martinez-Martinez L <i>et al</i>: Overexpression of <i>AmpC</i> and efflux pumps in <i>Pseudomonas aeruginosa</i> isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study. Antimicrobial agents and chemotherapy 2011, 55(5):1906-1911.</li> <li>Lee JY, Ko KS: OprD mutations and inactivation, expression of efflux pumps and AmpC, and metallo-β-lactamases in carbapenem-resistant <i>Pseudomonas aeruginosa</i> isolates from South Korea. International journal of antimicrobial agents 2012, 40(2):168-172.</li> <li>Juan C, Torrens G, González-Nicolau M, Oliver A: Diversity and regulation of intrinsic beta- lactamases from non-fermenting and other Gram-negative opportunistic pathogens. <i>FEMS Microbiol Rev</i> 2017, 41(6):781-815.</li> <li>Levy SB, Bonnie M: Antibacterial resistance worldwide: Causes, challenges and responses. <i>Nature Medicine</i> 2004, 10(125):5122-5129.</li> <li>Law COK, Huang C, Pan Q, Lee J, Hao Q, Chan T-F, Lo NWS, Ang IL, Koon A, Ip M <i>et al</i>: A small RNA transforms the multidrug resistance of <i>Pseudomonas aeruginosa</i> to drug susceptibility. <i>Mol Ther Nucleic Acids</i> 2019, 16:218-228.</li> <li>Robicsek A, Strahilevitz J, Jacoby GA, Macielag M, Abbanat D, Park CH, Bush K, Hooper DC: Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. <i>N</i></li></ul>	881	118.	Bassetti M, Vena A, Croxatto A, Righi E, Guery B: How to manage Pseudomonas aeruginosa
<ul> <li>Gurjar M: Colistin for lung infection: an update. <i>J Intensive Care</i> 2015, 3(1):3.</li> <li>Sabuda DM, Laupland K, Pitout J, Dalton B, Rabin H, Loule T, Conly J: Utilization of colistin for treatment of multidug-resistant <i>Pseudomonas aeruginosa</i>. <i>Can J Infect Dis Med Microbiol</i> 2008, 19(6):413-418.</li> <li>Li H, Luo YF, Williams BJ, Blackwell TS, Xie CM: Structure and function of OprD protein in <i>Pseudomonas aeruginosa</i>: from antibiotic resistance to novel therapies. <i>Int J Med Microbiol</i> 2012, 302(2):63-68.</li> <li>Cabot G, Ocampo-Sosa AA, Tubau F, Macia MD, Rodriguez C, Moya B, Zamorano L, Suarez C, Pena C, Martinez-Martinez L <i>et al</i>: Overexpression of <i>AmpC</i> and efflux pumps in <i>Pseudomonas aeruginosa</i> isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study. <i>Antimicrobial agents and chemotherapy</i> 2011, 55(5):1906-1911.</li> <li>Lee JY, Ko KS: OprD mutations and inactivation, expression of efflux pumps and AmpC, and metallo-β-lactamases in carbapenem-resistant <i>Pseudomonas aeruginosa</i> isolates from South Korea. <i>International journal of antimicrobial agents</i> 2012, 21:68-172.</li> <li>Juan C, Torrens G, González-Nicolau M, Oliver A: Diversity and regulation of intrinsic beta-lactamases from non-fermenting and other Gram-negative opportunistic pathogens. <i>FEMS Microbiol Rev</i> 2017, 41(6):781-815.</li> <li>Levy SB, Bonnie M: Antibacterial resistance worldwide: Causes, challenges and responses. <i>Nature Medicine</i> 2004, 10(125):S122-5129.</li> <li>Law COK, Huang C, Pan Q, Lee J, Hao Q, Chan T-F, Lo NWS, Ang IL, Koon A, Ip M <i>et al</i>: A small RNA transforms the multidrug resistance of <i>Pseudomonas aeruginosa</i> to drug susceptibility. <i>Mol Ther Nucleic Acids</i> 2019, 16:218-228.</li> <li>Law COK, Huang C, Pan Q, Lee J, Hao Q, Chan T-F, Lo NWS, Ang IL, Koon A, Ip M <i>et al</i>: A small RNA transforms the multidrug resistance of <i>Pseudomonas aeruginosa</i> to Whole-Gonome Sequence Data by USe of ARESdAb: an Analysis of Isolates from</li></ul>	882		i <b>nfections</b> . Drugs Context 2018, <b>7</b> :212527.
<ol> <li>Sabuda DM, Laupland K, Pitout J, Dalton B, Rabin H, Louie T, Conly J: Utilization of colistin for treatment of multidrug-resistant <i>Pseudomonas aeruginosa</i>. <i>Can J Infect Dis Med Microbiol</i> 2008, 19(6):413-418.</li> <li>Li H, Luo YF, Williams BJ, Blackwell TS, Xie CM: Structure and function of OpD protein in <i>Pseudomonas aeruginosa</i>: from antibiotic resistance to novel therapies. <i>Int J Med Microbiol</i> 2012, 302(2):63-68.</li> <li>Cabot G, Ocampo-Sosa AA, Tubau F, Macia MD, Rodriguez C, Moya B, Zamorano L, Suarez C, Pena C, Martinez-Martinez L <i>et al</i>: Overexpression of <i>AmpC</i> and efflux pumps in <i>Pseudomonas aeruginosa</i> isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study. <i>Antimicrobial agents and chemotherapy</i> 2011, 55(5):1906-1911.</li> <li>Lee JY, Ko KS: OprD mutations and inactivation, expression of efflux pumps and AmpC, and metallo-β-lactamases in carbapenem-resistant <i>Pseudomonas aeruginosa</i> isolates from South Korea. <i>International Journal of antimicrobial agents</i> 2012, 40(2):168-172.</li> <li>Juan C, Torrens G, González-Nicolau M, Oliver A: Diversity and regulation of intrinsic beta- lactamases from non-fermenting and other Gram-negative opportunistic pathogens. <i>FEMS Microbiol Rev</i> 2017, 41(6):781-815.</li> <li>Lev YS, B, Bonnie M: Anttibacterial resistance worldwide: Causes, challenges and responses. <i>Nature Medicine</i> 2004, 10(125):S122-S129.</li> <li>Law COK, Huang C, Pan Q, Lee J, Hao Q, Chan T-F, Lo NWS, Ang IL, Koon A, Ip M <i>et al</i>: A small RNA transforms the multidrug resistance of <i>Pseudomonas aeruginosa</i> to drug susceptibility. <i>Mol Ther Nucleic Acids</i> 2019, 16:218-228.</li> <li>Robicsek A, Strahilevitz J, Jacoby GA, Macielag M, Abbanat D, Park CH, Bush K, Hooper DC: Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. <i>Nat Med</i> 2006, 12(1):83-88.</li> <li>Ferreira I, Beisken S, Lueftinger L, Weinmaier T, Klein M, Bacher J, Patel R, von Haeseler A, Posc</li></ol>	883	119.	Gurjar M: Colistin for lung infection: an update. J Intensive Care 2015, 3(1):3.
<ul> <li>treatment of multidrug-resistant <i>Pseudomonas aeruginosa</i>. <i>Can J Infect Dis Med Microbiol</i> 2008, 19(6):413-418.</li> <li>Li H, Luo YF, Williams BJ, Blackwell TS, Xie CM: Structure and function of OprD protein in <i>Pseudomonas aeruginosa</i>: from antibiotic resistance to novel therapies. <i>Int J Med Microbiol</i> 2012, 302(2):63-68.</li> <li>Cabot G, Ocampo-Sosa AA, Tubau F, Macia MD, Rodriguez C, Moya B, Zamorano L, Suarez C, Pena C, Martinez-Martinez L <i>et al</i>: Overexpression of <i>AmpC</i> and efflux pumps in <i>Pseudomonas aeruginosa</i>: isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study. <i>Antimicrobial agents and chemotherapy</i> 2011, 55(5):1906-1911.</li> <li>Lee JY, Ko KS: OprD mutations and inactivation, expression of efflux pumps and AmpC, and metallo-β-lactamases in carbapenem-resistant <i>Pseudomonas aeruginosa</i> isolates from South Korea. <i>International journal of antimicrobial agents</i> 2012, 40(2):168-172.</li> <li>Juan C, Torrens G, González-Nicolau M, Oliver A: Diversity and regulation of intrinsic beta-lactamases from non-fermenting and other Gram-negative opportunistic pathogens. <i>FEMS Microbiol Rev</i> 2017, 41(6):781-815.</li> <li>Levy SB, Bonnie M: Antibacterial resistance worldwide: Causes, challenges and responses. <i>Nature Medicine</i> 2004, 10(125):5122-5129.</li> <li>Law COK, Huang C, Pan Q, Lee J, Hao Q, Chan T-F, Lo NWS, Ang IL, Koon A, Ip M <i>et al</i>: A small RNA transforms the multidrug resistance of <i>Pseudomonas aeruginosa</i> to drug susceptibility. <i>Mol Ther Nucleic Acids</i> 2019, 16:218-228.</li> <li>Robicsek A, Strahilevitz J, Jacoby GA, Macielag M, Abbanat D, Park CH, Bush K, Hooper DC: Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. <i>Nat Med</i> 2006, 12(1):83-88.</li> <li>Ferreira I, Beisken S, Lueftinger L, Weinmaier T, Klein M, Bacher J, Patel R, von Haeseler A, Posch AE: Species Identification and Antibiotic Resistance Preciction by Analysis of Whole-Gonome Sequenc</li></ul>	884	120.	Sabuda DM, Laupland K, Pitout J, Dalton B, Rabin H, Louie T, Conly J: Utilization of colistin for
<ul> <li>2008, 19(6):413-418.</li> <li>121. Li H, Luo YF, Williams BJ, Blackwell TS, Xie CM: Structure and function of OprD protein in <i>Pseudomonas aeruginosa:</i> from antibiotic resistance to novel therapies. Int J Med Microbiol 2012, 302(2):63-68.</li> <li>122. Cabot G, Ocampo-Sosa AA, Tubau F, Macia MD, Rodriguez C, Moya B, Zamorano L, Suarez C, Pena C, Martinez-Martinez L <i>et al:</i> Overexpression of <i>AmpC</i> and efflux pumps in <i>Pseudomonas aeruginosa</i> isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study. <i>Antimicrobial agents and chemotherapy</i> 2011, 55(5):1906-1911.</li> <li>123. Lee JY, Ko KS: OprD mutations and inactivation, expression of efflux pumps and AmpC, and metallo-β-lactamases in carbapenem-resistant <i>Pseudomonas aeruginosa</i> isolates from South Korea. International journal of antimicrobial agents 2012, 40(2):168-172.</li> <li>124. Juan C, Torrens G, González-Nicolau M, Oliver A: Diversity and regulation of intrinsic beta- lactamases from non-fermenting and other Gram-negative opportunistic pathogens. <i>FEMS Microbiol Rev</i> 2017, 41(6):781-815.</li> <li>125. Levy SB, Bonnie M: Antibacterial resistance worldwide: Causes, challenges and responses. <i>Nature Medicine</i> 2004, 10(125):S122-S129.</li> <li>126. Law COK, Huang C, Pan Q, Lee J, Hao Q, Chan T-F, Lo NWS, Ang IL, Koon A, Ip M <i>et al</i>: A small RNA transforms the multidrug resistance of <i>Pseudomonas aeruginosa</i> to drug susceptibility. <i>Mol Ther Nucleic Acids</i> 2019, 16:218-228.</li> <li>127. Robicsek A, Strahilevitz J, Jacoby GA, Macielag M, Abbanat D, Park CH, Bush K, Hooper DC: Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. <i>Nat Med</i> 2006, 12(1):83-88.</li> <li>128. Ferreira I, Beisken S, Lueftinger L, Weinmaier T, Klein M, Bacher J, Patel R, von Haeseler A, Posch AE: Species Identification and Antibiotic Resistance Prediction by Analysis of Whole- Genome Sequence Data by Use of ARESdb: an Analysis of Isolates from t</li></ul>	885		treatment of multidrug-resistant Pseudomonas aeruginosa. Can J Infect Dis Med Microbiol
<ol> <li>Li H, Luo YF, Williams BJ, Blackwell TS, Xie CM: Structure and function of OprD protein in <i>Pseudomonas aeruginosa</i>: from antibiotic resistance to novel therapies. Int J Med Microbiol 2012, 302(2):63-68.</li> <li>Cabot G, Ocampo-Sosa AA, Tubau F, Macia MD, Rodriguez C, Moya B, Zamorano L, Suarez C, Pena C, Martinez-Martinez L <i>et al.</i> Overexpression of <i>AmpC</i> and efflux pumps in <i>Pseudomonas aeruginosa</i> isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study. Antimicrobial agents and chemotherapy 2011, 55(5):1906-1911.</li> <li>Lee JY, Ko KS: OprD mutations and inactivation, expression of efflux pumps and AmpC, and metallo-β-lactamases in carbapenem-resistant <i>Pseudomonas aeruginosa</i> isolates from South Korea. International journal of antimicrobial agents 2012, 40(2):168-172.</li> <li>Juan C, Torrens G, González-Nicolau M, Oliver A: Diversity and regulation of intrinsic beta- lactamases from non-fermenting and other Gram-negative opportunistic pathogens. <i>FEMS Microbiol Rev</i> 2017, 41(6):781-815.</li> <li>Lev YSB, Bonnie M: Antibacterial resistance worldwide: Causes, challenges and responses. <i>Nature Medicine</i> 2004, 10(125):S122-S129.</li> <li>Law COK, Huang C, Pan Q, Lee J, Hao Q, Chan T-F, Lo NWS, Ang IL, Koon A, Ip M <i>et al</i>: A small RNA transforms the multidrug resistance of <i>Pseudomonas aeruginosa</i> to drug susceptibility. <i>Mol Ther Nucleic Acids</i> 2019, 16:218-228.</li> <li>Robicsek A, Strahilevitz J, Jacoby GA, Macielag M, Abbanat D, Park CH, Bush K, Hooper DC: Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. <i>Nat Med</i> 2006, 12(1):83-88.</li> <li>Ferreira I, Beisken S, Lueftinger L, Weinmaier T, Klein M, Bacher J, Patel R, von Haeseler A, Posch AE: Species Identification and Antibiotic Resistance Prediction by Analysis of Whole- Genome Sequence Data by Use of ARESdb: an Analysis of Isolates from the Unyvero Lower Respiratory Tract Infection Trial. <i>Journal of clinical mic</i></li></ol>	886		2008, <b>19</b> (6):413-418.
<ul> <li>Pseudomonas aeruginosa: from antibiotic resistance to novel therapies. Int J Med Microbiol 2012, 302(2):63-68.</li> <li>Cabot G, Ocampo-Sosa AA, Tubau F, Macia MD, Rodriguez C, Moya B, Zamorano L, Suarez C, Pena C, Martinez-Martinez L <i>et al</i>: Overexpression of <i>AmpC</i> and efflux pumps in <i>Pseudomonas aeruginosa</i> isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study. Antimicrobial agents and chemotherapy 2011, 55(5):1906-1911.</li> <li>Lee JY, Ko KS: OprD mutations and inactivation, expression of efflux pumps and AmpC, and metallo-B-lactamases in carbapenem-resistant <i>Pseudomonas aeruginosa</i> isolates from South Korea. International journal of antimicrobial agents 2012, 40(2):168-172.</li> <li>Juan C, Torrens G, González-Nicolau M, Oliver A: Diversity and regulation of intrinsic beta- lactamases from non-fermenting and other Gram-negative opportunistic pathogens. <i>FEMS</i> <i>Microbiol Rev</i> 2017, 41(6):781-815.</li> <li>Levy SB, Bonnie M: Antibacterial resistance worldwide: Causes, challenges and responses. <i>Nature Medicine</i> 2004, 10(125):S122-S129.</li> <li>Lew COK, Huang C, Pan Q, Lee J, Hao Q, Chan T-F, Lo NWS, Ang IL, Koon A, Ip M <i>et al</i>: A small RNA transforms the multidrug resistance of <i>Pseudomonas aeruginosa</i> to drug susceptibility. <i>Mol Ther Nucleic Acids</i> 2019, 16:218-228.</li> <li>Robicsek A, Strahilevitz J, Jacoby GA, Macielag M, Abbanat D, Park CH, Bush K, Hooper DC: Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. <i>Nat Med</i> 2006, 12(1):83-88.</li> <li>Rereira I, Beisken S, Lueftinger L, Weinmaier T, Klein M, Bacher J, Patel R, von Haeseler A, Posch AE: Species Identification and Antibiotic Resistance Prediction by Analysis of Whole- Genome Sequence Data by Use of ARESdb: an Analysis of Isolates from the Unyvero Lower Respiratory Tract Infection Trial. <i>Journal of clinical microbiology</i> 2020, 58(7).</li> <li>Potsch A, Becker T, Pommerneke C, Magnowska Z, Jänsch L</li></ul>	887	121.	Li H, Luo YF, Williams BJ, Blackwell TS, Xie CM: Structure and function of OprD protein in
<ul> <li>2012, 302(2):63-68.</li> <li>122. Cabot G, Ocampo-Sosa AA, Tubau F, Macia MD, Rodriguez C, Moya B, Zamorano L, Suarez C, Pena C, Martinez-Martinez L <i>et al</i>. Overexpression of <i>AmpC</i> and efflux pumps in <i>Pseudomonas aeruginosa</i> isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study. Antimicrobial agents and chemotherapy 2011, 55(5):1906-1911.</li> <li>123. Lee JY, Ko KS: OprD mutations and inactivation, expression of efflux pumps and AmpC, and metallo-B-latamases in carbapenem-resistant <i>Pseudomonas aeruginosa</i> isolates from South Korea. International journal of antimicrobial agents 2012, 40(2):168-172.</li> <li>124. Juan C, Torrens G, González-Nicolau M, Oliver A: Diversity and regulation of intrinsic beta- lactamases from non-fermenting and other Gram-negative opportunistic pathogens. <i>FEMS</i> <i>Microbiol Rev</i> 2017, 41(6):781-815.</li> <li>125. Levy SB, Bonnie M: Antibacterial resistance worldwide: Causes, challenges and responses. <i>Nature Medicine</i> 2004, 10(125):S122-S129.</li> <li>126. Law COK, Huang C, Pan Q, Lee J, Hao Q, Chan T-F, Lo NWS, Ang IL, Koon A, Ip M <i>et al</i>: A small RNA transforms the multidrug resistance of <i>Pseudomonas aeruginosa</i> to drug susceptibility. <i>Mol Ther Nucleic Acids</i> 2019, 16:218-228.</li> <li>127. Robicsek A, Strahilevitz J, Jacoby GA, Macielag M, Abbanat D, Park CH, Bush K, Hooper DC: Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. <i>Nat Med</i> 2006, 12(1):83-88.</li> <li>128. Ferreira I, Beisken S, Lueftinger L, Weinmaier T, Klein M, Bacher J, Patel R, von Haeseler A, Posch AE: Species Identification and Antibiotic Resistance Prediction by Analysis of Whole- Genome Sequence Data by Use of ARESdb: an Analysis of Isolates from the Unyvero Lower Respiratory Tract Infection Trial. <i>Journal of clinical microbiolagy</i> 2020, S8(7).</li> <li>129. Dötsch A, Becker T, Pommerenke C, Magnowska Z, Jänsch L, Häussler S: Genomewide identification of genetic</li></ul>	888		Pseudomonas aeruginosa: from antibiotic resistance to novel therapies. Int J Med Microbiol
<ol> <li>Cabot G, Ocampo-Sosa AA, Tubau F, Macia MD, Rodriguez C, Moya B, Zamorano L, Suarez C, Pena C, Martinez-Martinez L <i>et al</i>: Overexpression of <i>AmpC</i> and efflux pumps in <i>Pseudomonas aeruginosa</i> isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study. <i>Antimicrobial agents and chemotherapy</i> 2011, 55(5):1906-1911.</li> <li>Lee JY, Ko KS: OprD mutations and inactivation, expression of efflux pumps and AmpC, and metallo-β-lactamases in carbapenem-resistant <i>Pseudomonas aeruginosa</i> isolates from South Korea. <i>International journal of antimicrobial agents</i> 2012, 40(2):168-172.</li> <li>Juan C, Torrens G, González-Nicolau M, Oliver A: Diversity and regulation of intrinsic beta- lactamases from non-fermenting and other Gram-negative opportunistic pathogens. <i>FEMS</i> <i>Microbiol Rev</i> 2017, 41(6):781-815.</li> <li>Levy SB, Bonnie M: Antibacterial resistance worldwide: Causes, challenges and responses. <i>Nature Medicine</i> 2004, 10(125):S122-S129.</li> <li>Law COK, Huang C, Pan Q, Lee J, Hao Q, Chan T-F, Lo NWS, Ang IL, Koon A, Ip M <i>et al</i>: A small RNA transforms the multidrug resistance of <i>Pseudomonas aeruginosa</i> to drug susceptibility. <i>Mol Ther Nucleic Acids</i> 2019, 16:218-228.</li> <li>Robicsek A, Strahilevitz J, Jacoby GA, Macielag M, Abbanat D, Park CH, Bush K, Hooper DC: Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. <i>Nat Med</i> 2006, 12(1):83-88.</li> <li>Ferreira I, Beisken S, Lueftinger L, Weinmaier T, Klein M, Bacher J, Patel R, von Haeseler A, Posch AE: Species Identification and Antibiotic Resistance Prediction by Analysis of Whole- Genome Sequence Data by Use of ARESdb: an Analysis of Isolates from the Unyvero Lower Respiratory Tract Infection Trial. <i>Journal of clinical microbiology</i> 2020, 58(7).</li> <li>Dötsch A, Becker T, Pommerenke C, Magnowska Z, Jänsch L, Häusler S: Genomewide identification of genetic determinants of antimicrobial drug resistance in <i>Pseudomonas</i> <i>aeru</i></li></ol>	889		2012, <b>302</b> (2):63-68.
<ul> <li>Pena C, Martinez-Martinez L et al: Overexpression of AmpC and efflux pumps in</li> <li><i>Pseudomonas aeruginosa</i> isolates from bloodstream infections: prevalence and impact on</li> <li>resistance in a Spanish multicenter study. Antimicrobial agents and chemotherapy 2011,</li> <li>S5(5):1906-1911.</li> <li>Lee JY, Ko KS: OprD mutations and inactivation, expression of efflux pumps and AmpC, and</li> <li>metallo-β-lactamases in carbapenem-resistant <i>Pseudomonas aeruginosa</i> isolates from South</li> <li>Korea. International journal of antimicrobial agents 2012, 40(2):168-172.</li> <li>Juan C, Torrens G, González-Nicolau M, Oliver A: Diversity and regulation of intrinsic beta-</li> <li>lactamases from non-fermenting and other Gram-negative opportunistic pathogens. <i>FEMS</i></li> <li>Microbiol Rev 2017, 41(6):781-815.</li> <li>Levy SB, Bonnie M: Antibacterial resistance worldwide: Causes, challenges and responses.</li> <li><i>Nature Medicine</i> 2004, 10(125):S122-S129.</li> <li>Law COK, Huang C, Pan Q, Lee J, Hao Q, Chan T-F, Lo NWS, Ang IL, Koon A, Ip M et al: A small</li> <li>RNA transforms the multidrug resistance of <i>Pseudomonas aeruginosa</i> to drug susceptibility.</li> <li><i>Mol Ther Nucleic Acids</i> 2019, 16:218-228.</li> <li>I27. Robicsek A, Strahilevitz J, Jacoby GA, Macielag M, Abbanat D, Park CH, Bush K, Hooper DC:</li> <li>Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside</li> <li>acetyltransferase. <i>Nat Med</i> 2006, 12(1):83-88.</li> <li>I28. Ferreira I, Beisken S, Lueftinger L, Weinmaier T, Klein M, Bacher J, Patel R, von Haeseler A,</li> <li>Posch AE: Species Identification and Antibiotic Resistance Prediction by Analysis of Whole-</li> <li>Genome Sequence Data by Use of ARESdb: an Analysis of Isolates from the Unyvero Lower</li> <li>Respiratory Tract Infection Trial. <i>Journal of clinical microbiology</i> 2020, 58(7).</li> <li>Dötsch A, Becker T, Pommerneke C, Magnowska Z, Jänsch L, Häusler S:</li></ul>	890	122.	Cabot G, Ocampo-Sosa AA, Tubau F, Macia MD, Rodriguez C, Moya B, Zamorano L, Suarez C,
<ul> <li><i>Pseudomonas aeruginosa</i> isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study. Antimicrobial agents and chemotherapy 2011, 55(5):1906-1911.</li> <li>123. Lee JY, Ko KS: OprD mutations and inactivation, expression of efflux pumps and AmpC, and metallo-β-lactamases in carbapenem-resistant <i>Pseudomonas aeruginosa</i> isolates from South Korea. International journal of antimicrobial agents 2012, 40(2):168-172.</li> <li>124. Juan C, Torrens G, González-Nicolau M, Oliver A: Diversity and regulation of intrinsic beta- lactamases from non-fermenting and other Gram-negative opportunistic pathogens. <i>FEMS</i> <i>Microbiol Rev</i> 2017, 41(6):781-815.</li> <li>125. Levy SB, Bonnie M: Antibacterial resistance worldwide: Causes, challenges and responses. <i>Nature Medicine</i> 2004, 10(125):S122-S129.</li> <li>126. Law COK, Huang C, Pan Q, Lee J, Hao Q, Chan T-F, Lo NWS, Ang IL, Koon A, Ip M <i>et al</i>: A small RNA transforms the multidrug resistance of <i>Pseudomonas aeruginosa</i> to drug susceptibility. <i>Mol Ther Nucleic Acids</i> 2019, 16:218-228.</li> <li>127. Robicsek A, Strahilevitz J, Jacoby GA, Macielag M, Abbanat D, Park CH, Bush K, Hooper DC: Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. <i>Nat Med</i> 2006, 12(1):83-88.</li> <li>128. Ferreira I, Beisken S, Lueftinger L, Weinmaier T, Klein M, Bacher J, Patel R, von Haeseler A, Posch AE: Species Identification and Antibiotic Resistance Prediction by Analysis of Whole- Genome Sequence Data by Use of ARESbb: an Analysis of Isolates from the Unyvero Lower Respiratory Tract Infection Trial. <i>Journal of clinical microbiology</i> 2020, 58(7).</li> <li>129. Dötsch A, Becker T, Pommerenke C, Magnowska Z, Jänsch L, Häussler S: Genomewide identification of genetic determinants of antimicrobial drug resistance in <i>Pseudomonas</i> <i>aeruginosa</i>. <i>Antimicrobial agents and chemotherapy</i> 2009, 53(6):2522-2531.</li> </ul>	891		Pena C, Martinez-Martinez L et al: Overexpression of AmpC and efflux pumps in
<ul> <li>resistance in a Spanish multicenter study. Antimicrobial agents and chemotherapy 2011, 55(5):1906-1911.</li> <li>Lee JY, Ko KS: OprD mutations and inactivation, expression of efflux pumps and AmpC, and metallo-β-lactamases in carbapenem-resistant <i>Pseudomonas aeruginosa</i> isolates from South Korea. International journal of antimicrobial agents 2012, 40(2):168-172.</li> <li>Juan C, Torrens G, González-Nicolau M, Oliver A: Diversity and regulation of intrinsic beta- lactamases from non-fermenting and other Gram-negative opportunistic pathogens. <i>FEMS</i> <i>Microbiol Rev</i> 2017, 41(6):781-815.</li> <li>Levy SB, Bonnie M: Antibacterial resistance worldwide: Causes, challenges and responses. <i>Nature Medicine</i> 2004, 10(12S):S122-S129.</li> <li>Law COK, Huang C, Pan Q, Lee J, Hao Q, Chan T-F, Lo NWS, Ang IL, Koon A, Ip M <i>et al</i>: A small RNA transforms the multidrug resistance of <i>Pseudomonas aeruginosa</i> to drug susceptibility. <i>Mol Ther Nucleic Acids</i> 2019, 16:218-228.</li> <li>Robicsek A, Strahilevitz J, Jacoby GA, Macielag M, Abbanat D, Park CH, Bush K, Hooper DC: Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. <i>Nat Med</i> 2006, 12(1):83-88.</li> <li>128. Ferreira I, Beisken S, Lueftinger L, Weinmaier T, Klein M, Bacher J, Patel R, von Haeseler A, Posch AE: Species Identification and Antibiotic Resistance Prediction by Analysis of Whole- Genome Sequence Data by Use of ARES0b: an Angiss of Isolates from the Unyvero Lower Respiratory Tract Infection Trial. <i>Journal of clinical microbiology</i> 2020, 58(7).</li> <li>129. Dötsch A, Becker T, Pommerenke C, Magnowska Z, Jänsch L, Häussler S: Genomewide identification of genetic determinants of antimicrobial drug resistance in <i>Pseudomonas</i> <i>aeruginosa</i>. Antimicrobial agents and chemotherapy 2009, 53(6):2522-2531.</li> </ul>	892		Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on
<ul> <li>55(5):1906-1911.</li> <li>123. Lee JY, Ko KS: OprD mutations and inactivation, expression of efflux pumps and AmpC, and metallo-β-lactamases in carbapenem-resistant <i>Pseudomonas aeruginosa</i> isolates from South Korea. International journal of antimicrobial agents 2012, 40(2):168-172.</li> <li>124. Juan C, Torrens G, González-Nicolau M, Oliver A: Diversity and regulation of intrinsic beta- lactamases from non-fermenting and other Gram-negative opportunistic pathogens. <i>FEMS</i> <i>Microbiol Rev</i> 2017, 41(6):781-815.</li> <li>125. Levy SB, Bonnie M: Antibacterial resistance worldwide: Causes, challenges and responses. <i>Nature Medicine</i> 2004, 10(125):5122-5129.</li> <li>126. Law COK, Huang C, Pan Q, Lee J, Hao Q, Chan T-F, Lo NWS, Ang IL, Koon A, Ip M <i>et al</i>: A small RNA transforms the multidrug resistance of <i>Pseudomonas aeruginosa</i> to drug susceptibility. <i>Mol Ther Nucleic Acids</i> 2019, 16:218-228.</li> <li>127. Robicsek A, Strahilevitz J, Jacoby GA, Macielag M, Abbanat D, Park CH, Bush K, Hooper DC: Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. <i>Nat Med</i> 2006, 12(1):83-88.</li> <li>128. Ferreira I, Beisken S, Lueftinger L, Weinmaier T, Klein M, Bacher J, Patel R, von Haeseler A, Posch AE: Species Identification and Antibiotic Resistance Prediction by Analysis of Whole- Genome Sequence Data by Use of ARESdb: an Analysis of Isolates from the Unyvero Lower Respiratory Tract Infection Trial. <i>Journal of clinical microbiology</i> 2020, 58(7).</li> <li>129. Dötsch A, Becker T, Pommerenke C, Magnowska Z, Jänsch L, Häussler S: Genomewide identification of genetic determinants of antimicrobial drug resistance in <i>Pseudomonas</i> <i>aeruginosa</i>. <i>Antimicrobial agents and chemotherapy</i> 2009, 53(6):2522-2531.</li> </ul>	893		resistance in a Spanish multicenter study. Antimicrobial agents and chemotherapy 2011,
<ul> <li>Lee JY, Ko KS: OprD mutations and inactivation, expression of efflux pumps and AmpC, and metallo-β-lactamases in carbapenem-resistant <i>Pseudomonas aeruginosa</i> isolates from South Korea. International journal of antimicrobial agents 2012, 40(2):168-172.</li> <li>Juan C, Torrens G, González-Nicolau M, Oliver A: Diversity and regulation of intrinsic beta- lactamases from non-fermenting and other Gram-negative opportunistic pathogens. <i>FEMS</i> <i>Microbiol Rev</i> 2017, 41(6):781-815.</li> <li>Levy SB, Bonnie M: Antibacterial resistance worldwide: Causes, challenges and responses. <i>Nature Medicine</i> 2004, 10(125):S122-S129.</li> <li>Law COK, Huang C, Pan Q, Lee J, Hao Q, Chan T-F, Lo NWS, Ang IL, Koon A, Ip M <i>et al</i>: A small RNA transforms the multidrug resistance of <i>Pseudomonas aeruginosa</i> to drug susceptibility. <i>Mol Ther Nucleic Acids</i> 2019, 16:218-228.</li> <li>127. Robicsek A, Strahilevitz J, Jacoby GA, Macielag M, Abbanat D, Park CH, Bush K, Hooper DC: Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. <i>Nat Med</i> 2006, 12(1):83-88.</li> <li>Ferreira I, Beisken S, Lueftinger L, Weinmaier T, Klein M, Bacher J, Patel R, von Haeseler A, Posch AE: Species Identification and Antibiotic Resistance Prediction by Analysis of Whole- Genome Sequence Data by Use of ARESdb: an Analysis of Isolates from the Unyvero Lower Respiratory Tract Infection Trial. <i>Journal of clinical microbiology</i> 2020, 58(7).</li> <li>Dötsch A, Becker T, Pommerenke C, Magnowska Z, Jänsch L, Häussler S: Genomewide identification of genetic determinants of antimicrobial drug resistance in <i>Pseudomonas</i> <i>aeruginosa</i>. <i>Antimicrobial agents and chemotherapy</i> 2009, 53(6):2522-2531.</li> </ul>	894		<b>55</b> (5):1906-1911.
<ul> <li>metallo-β-lactamases in carbapenem-resistant <i>Pseudomonas aeruginosa</i> isolates from South Korea. International journal of antimicrobial agents 2012, 40(2):168-172.</li> <li>124. Juan C, Torrens G, González-Nicolau M, Oliver A: Diversity and regulation of intrinsic beta- lactamases from non-fermenting and other Gram-negative opportunistic pathogens. <i>FEMS</i> <i>Microbiol Rev</i> 2017, 41(6):781-815.</li> <li>125. Levy SB, Bonnie M: Antibacterial resistance worldwide: Causes, challenges and responses. <i>Nature Medicine</i> 2004, 10(12S):S122-S129.</li> <li>126. Law COK, Huang C, Pan Q, Lee J, Hao Q, Chan T-F, Lo NWS, Ang IL, Koon A, Ip M <i>et al</i>: A small RNA transforms the multidrug resistance of <i>Pseudomonas aeruginosa</i> to drug susceptibility. <i>Mol Ther Nucleic Acids</i> 2019, 16:218-228.</li> <li>127. Robicsek A, Strahilevitz J, Jacoby GA, Macielag M, Abbanat D, Park CH, Bush K, Hooper DC: Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. <i>Nat Med</i> 2006, 12(1):83-88.</li> <li>128. Ferreira I, Beisken S, Lueftinger L, Weinmaier T, Klein M, Bacher J, Patel R, von Haeseler A, Posch AE: Species Identification and Antibiotic Resistance Prediction by Analysis of Whole- Genome Sequence Data by Use of ARESdb: an Analysis of Isolates from the Unyvero Lower Respiratory Tract Infection Trial. <i>Journal of clinical microbiology</i> 2020, 58(7).</li> <li>129. Dötsch A, Becker T, Pommerenke C, Magnowska Z, Jänsch L, Häussler S: Genomewide identification of genetic determinants of antimicrobial drug resistance in <i>Pseudomonas</i> <i>aeruginosa</i>. <i>Antimicrobial agents and chemotherapy</i> 2009, 53(6):2522-2531.</li> </ul>	895	123.	Lee JY, Ko KS: OprD mutations and inactivation, expression of efflux pumps and AmpC, and
<ul> <li>Korea. International journal of antimicrobial agents 2012, 40(2):168-172.</li> <li>Juan C, Torrens G, González-Nicolau M, Oliver A: Diversity and regulation of intrinsic beta- lactamases from non-fermenting and other Gram-negative opportunistic pathogens. <i>FEMS</i> <i>Microbiol Rev</i> 2017, 41(6):781-815.</li> <li>Levy SB, Bonnie M: Antibacterial resistance worldwide: Causes, challenges and responses. <i>Nature Medicine</i> 2004, 10(125):S122-S129.</li> <li>Law COK, Huang C, Pan Q, Lee J, Hao Q, Chan T-F, Lo NWS, Ang IL, Koon A, Ip M <i>et al</i>: A small RNA transforms the multidrug resistance of <i>Pseudomonas aeruginosa</i> to drug susceptibility. <i>Mol Ther Nucleic Acids</i> 2019, 16:218-228.</li> <li>Robicsek A, Strahilevitz J, Jacoby GA, Macielag M, Abbanat D, Park CH, Bush K, Hooper DC: Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. <i>Nat Med</i> 2006, 12(1):83-88.</li> <li>Ferreira I, Beisken S, Lueftinger L, Weinmaier T, Klein M, Bacher J, Patel R, von Haeseler A, Posch AE: Species Identification and Antibiotic Resistance Prediction by Analysis of Whole- Genome Sequence Data by Use of ARESdb: an Analysis of Isolates from the Unyvero Lower Respiratory Tract Infection Trial. <i>Journal of clinical microbiology</i> 2020, 58(7).</li> <li>Dötsch A, Becker T, Pommerenke C, Magnowska Z, Jänsch L, Häussler S: Genomewide identification of genetic determinants of antimicrobial drug resistance in <i>Pseudomonas</i> <i>aeruginosa</i>. <i>Antimicrobial agents and chemotherapy</i> 2009, 53(6):2522-2531.</li> </ul>	896		metallo-β-lactamases in carbapenem-resistant <i>Pseudomonas aeruginosa</i> isolates from South
<ul> <li>Juan C, Torrens G, González-Nicolau M, Oliver A: Diversity and regulation of intrinsic beta- lactamases from non-fermenting and other Gram-negative opportunistic pathogens. <i>FEMS</i> <i>Microbiol Rev</i> 2017, 41(6):781-815.</li> <li>Levy SB, Bonnie M: Antibacterial resistance worldwide: Causes, challenges and responses. <i>Nature Medicine</i> 2004, 10(12S):S122-S129.</li> <li>Law COK, Huang C, Pan Q, Lee J, Hao Q, Chan T-F, Lo NWS, Ang IL, Koon A, Ip M <i>et al</i>: A small RNA transforms the multidrug resistance of <i>Pseudomonas aeruginosa</i> to drug susceptibility. <i>Mol Ther Nucleic Acids</i> 2019, 16:218-228.</li> <li>Robicsek A, Strahilevitz J, Jacoby GA, Macielag M, Abbanat D, Park CH, Bush K, Hooper DC: Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. <i>Nat Med</i> 2006, 12(1):83-88.</li> <li>Ferreira I, Beisken S, Lueftinger L, Weinmaier T, Klein M, Bacher J, Patel R, von Haeseler A, Posch AE: Species Identification and Antibiotic Resistance Prediction by Analysis of Whole- Genome Sequence Data by Use of ARESdb: an Analysis of Isolates from the Unyvero Lower Respiratory Tract Infection Trial. <i>Journal of clinical microbiology</i> 2020, 58(7).</li> <li>Dötsch A, Becker T, Pommerenke C, Magnowska Z, Jänsch L, Häussler S: Genomewide identification of genetic determinants of antimicrobial drug resistance in <i>Pseudomonas</i> <i>aeruginosa</i>. <i>Antimicrobial agents and chemotherapy</i> 2009, 53(6):2522-2531.</li> </ul>	897		Korea. International journal of antimicrobial agents 2012, <b>40</b> (2):168-172.
899lactamases from non-fermenting and other Gram-negative opportunistic pathogens. FEMS900Microbiol Rev 2017, 41(6):781-815.901125.Levy SB, Bonnie M: Antibacterial resistance worldwide: Causes, challenges and responses.902Nature Medicine 2004, 10(12S):S122-S129.903126.Law COK, Huang C, Pan Q, Lee J, Hao Q, Chan T-F, Lo NWS, Ang IL, Koon A, Ip M et al: A small904RNA transforms the multidrug resistance of Pseudomonas aeruginosa to drug susceptibility.905Mol Ther Nucleic Acids 2019, 16:218-228.906127.Robicsek A, Strahilevitz J, Jacoby GA, Macielag M, Abbanat D, Park CH, Bush K, Hooper DC:907Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside908acetyltransferase. Nat Med 2006, 12(1):83-88.909128.Ferreira I, Beisken S, Lueftinger L, Weinmaier T, Klein M, Bacher J, Patel R, von Haeseler A,910Posch AE: Species Identification and Antibiotic Resistance Prediction by Analysis of Whole-911Genome Sequence Data by Use of ARESdb: an Analysis of Isolates from the Unyvero Lower912Respiratory Tract Infection Trial. Journal of clinical microbiology 2020, 58(7).913129.Dötsch A, Becker T, Pommerenke C, Magnowska Z, Jänsch L, Häussler S: Genomewide914identification of genetic determinants of antimicrobial drug resistance in Pseudomonas915aeruginosa. Antimicrobial agents and chemotherapy 2009, 53(6):2522-2531.	898	124.	Juan C, Torrens G, González-Nicolau M, Oliver A: Diversity and regulation of intrinsic beta-
<ul> <li>Microbiol Rev 2017, 41(6):781-815.</li> <li>125. Levy SB, Bonnie M: Antibacterial resistance worldwide: Causes, challenges and responses. Nature Medicine 2004, 10(12S):S122-S129.</li> <li>126. Law COK, Huang C, Pan Q, Lee J, Hao Q, Chan T-F, Lo NWS, Ang IL, Koon A, Ip M <i>et al</i>: A small RNA transforms the multidrug resistance of <i>Pseudomonas aeruginosa</i> to drug susceptibility. Mol Ther Nucleic Acids 2019, 16:218-228.</li> <li>127. Robicsek A, Strahilevitz J, Jacoby GA, Macielag M, Abbanat D, Park CH, Bush K, Hooper DC: Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. Nat Med 2006, 12(1):83-88.</li> <li>128. Ferreira I, Beisken S, Lueftinger L, Weinmaier T, Klein M, Bacher J, Patel R, von Haeseler A, Posch AE: Species Identification and Antibiotic Resistance Prediction by Analysis of Whole- Genome Sequence Data by Use of ARESdb: an Analysis of Isolates from the Unyvero Lower Respiratory Tract Infection Trial. <i>Journal of clinical microbiology</i> 2020, 58(7).</li> <li>129. Dötsch A, Becker T, Pommerenke C, Magnowska Z, Jänsch L, Häussler S: Genomewide identification of genetic determinants of antimicrobial drug resistance in <i>Pseudomonas</i> <i>aeruginosa</i>. Antimicrobial agents and chemotherapy 2009, 53(6):2522-2531.</li> </ul>	899		lactamases from non-fermenting and other Gram-negative opportunistic pathogens. FEMS
<ul> <li>125. Levy SB, Bonnie M: Antibacterial resistance worldwide: Causes, challenges and responses. <i>Nature Medicine</i> 2004, 10(12S):S122-S129.</li> <li>126. Law COK, Huang C, Pan Q, Lee J, Hao Q, Chan T-F, Lo NWS, Ang IL, Koon A, Ip M <i>et al</i>: A small RNA transforms the multidrug resistance of <i>Pseudomonas aeruginosa</i> to drug susceptibility. <i>Mol Ther Nucleic Acids</i> 2019, 16:218-228.</li> <li>127. Robicsek A, Strahilevitz J, Jacoby GA, Macielag M, Abbanat D, Park CH, Bush K, Hooper DC: Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. <i>Nat Med</i> 2006, 12(1):83-88.</li> <li>128. Ferreira I, Beisken S, Lueftinger L, Weinmaier T, Klein M, Bacher J, Patel R, von Haeseler A, Posch AE: Species Identification and Antibiotic Resistance Prediction by Analysis of Whole- Genome Sequence Data by Use of ARESdb: an Analysis of Isolates from the Unyvero Lower Respiratory Tract Infection Trial. <i>Journal of clinical microbiology</i> 2020, 58(7).</li> <li>129. Dötsch A, Becker T, Pommerenke C, Magnowska Z, Jänsch L, Häussler S: Genomewide identification of genetic determinants of antimicrobial drug resistance in <i>Pseudomonas</i> <i>aeruginosa</i>. <i>Antimicrobial agents and chemotherapy</i> 2009, 53(6):2522-2531.</li> </ul>	900		Microbiol Rev 2017, <b>41</b> (6):781-815.
<ul> <li>Nature Medicine 2004, 10(125):S122-S129.</li> <li>126. Law COK, Huang C, Pan Q, Lee J, Hao Q, Chan T-F, Lo NWS, Ang IL, Koon A, Ip M <i>et al</i>: A small RNA transforms the multidrug resistance of <i>Pseudomonas aeruginosa</i> to drug susceptibility. <i>Mol Ther Nucleic Acids</i> 2019, 16:218-228.</li> <li>127. Robicsek A, Strahilevitz J, Jacoby GA, Macielag M, Abbanat D, Park CH, Bush K, Hooper DC: Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. <i>Nat Med</i> 2006, 12(1):83-88.</li> <li>128. Ferreira I, Beisken S, Lueftinger L, Weinmaier T, Klein M, Bacher J, Patel R, von Haeseler A, Posch AE: Species Identification and Antibiotic Resistance Prediction by Analysis of Whole- Genome Sequence Data by Use of ARESdb: an Analysis of Isolates from the Unyvero Lower Respiratory Tract Infection Trial. <i>Journal of clinical microbiology</i> 2020, 58(7).</li> <li>129. Dötsch A, Becker T, Pommerenke C, Magnowska Z, Jänsch L, Häussler S: Genomewide identification of genetic determinants of antimicrobial drug resistance in <i>Pseudomonas</i> <i>aeruginosa</i>. <i>Antimicrobial agents and chemotherapy</i> 2009, 53(6):2522-2531.</li> </ul>	901	125.	Levy SB, Bonnie M: Antibacterial resistance worldwide: Causes, challenges and responses.
<ul> <li>Law COK, Huang C, Pan Q, Lee J, Hao Q, Chan T-F, Lo NWS, Ang IL, Koon A, Ip M <i>et al</i>: A small RNA transforms the multidrug resistance of <i>Pseudomonas aeruginosa</i> to drug susceptibility. <i>Mol Ther Nucleic Acids</i> 2019, 16:218-228.</li> <li>Robicsek A, Strahilevitz J, Jacoby GA, Macielag M, Abbanat D, Park CH, Bush K, Hooper DC: Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. <i>Nat Med</i> 2006, 12(1):83-88.</li> <li>Ferreira I, Beisken S, Lueftinger L, Weinmaier T, Klein M, Bacher J, Patel R, von Haeseler A, Posch AE: Species Identification and Antibiotic Resistance Prediction by Analysis of Whole- Genome Sequence Data by Use of ARESdb: an Analysis of Isolates from the Unyvero Lower Respiratory Tract Infection Trial. <i>Journal of clinical microbiology</i> 2020, 58(7).</li> <li>Dötsch A, Becker T, Pommerenke C, Magnowska Z, Jänsch L, Häussler S: Genomewide identification of genetic determinants of antimicrobial drug resistance in <i>Pseudomonas</i> <i>aeruginosa</i>. <i>Antimicrobial agents and chemotherapy</i> 2009, 53(6):2522-2531.</li> </ul>	902		Nature Medicine 2004, <b>10</b> (12S):S122-S129.
904RNA transforms the multidrug resistance of <i>Pseudomonas aeruginosa</i> to drug susceptibility.905Mol Ther Nucleic Acids 2019, 16:218-228.906127.907Robicsek A, Strahilevitz J, Jacoby GA, Macielag M, Abbanat D, Park CH, Bush K, Hooper DC:907Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside908acetyltransferase. Nat Med 2006, 12(1):83-88.909128.909128.909Ferreira I, Beisken S, Lueftinger L, Weinmaier T, Klein M, Bacher J, Patel R, von Haeseler A,910Posch AE: Species Identification and Antibiotic Resistance Prediction by Analysis of Whole-911Genome Sequence Data by Use of ARESdb: an Analysis of Isolates from the Unyvero Lower912Respiratory Tract Infection Trial. Journal of clinical microbiology 2020, 58(7).913129.Dötsch A, Becker T, Pommerenke C, Magnowska Z, Jänsch L, Häussler S: Genomewide914identification of genetic determinants of antimicrobial drug resistance in Pseudomonas915aeruginosa. Antimicrobial agents and chemotherapy 2009, 53(6):2522-2531.	903	126.	Law COK, Huang C, Pan Q, Lee J, Hao Q, Chan T-F, Lo NWS, Ang IL, Koon A, Ip M <i>et al</i> : <b>A small</b>
<ul> <li>Mol Ther Nucleic Acids 2019, 16:218-228.</li> <li>Robicsek A, Strahilevitz J, Jacoby GA, Macielag M, Abbanat D, Park CH, Bush K, Hooper DC:</li> <li>Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside</li> <li>acetyltransferase. Nat Med 2006, 12(1):83-88.</li> <li>Ferreira I, Beisken S, Lueftinger L, Weinmaier T, Klein M, Bacher J, Patel R, von Haeseler A,</li> <li>Posch AE: Species Identification and Antibiotic Resistance Prediction by Analysis of Whole-</li> <li>Genome Sequence Data by Use of ARESdb: an Analysis of Isolates from the Unyvero Lower</li> <li>Respiratory Tract Infection Trial. Journal of clinical microbiology 2020, 58(7).</li> <li>Dötsch A, Becker T, Pommerenke C, Magnowska Z, Jänsch L, Häussler S: Genomewide</li> <li>identification of genetic determinants of antimicrobial drug resistance in Pseudomonas</li> <li>aeruginosa. Antimicrobial agents and chemotherapy 2009, 53(6):2522-2531.</li> </ul>	904		RNA transforms the multidrug resistance of <i>Pseudomonas aeruginosa</i> to drug susceptibility.
<ul> <li>Robicsek A, Strahilevitz J, Jacoby GA, Macielag M, Abbanat D, Park CH, Bush K, Hooper DC:</li> <li>Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside</li> <li>acetyltransferase. Nat Med 2006, 12(1):83-88.</li> <li>Ferreira I, Beisken S, Lueftinger L, Weinmaier T, Klein M, Bacher J, Patel R, von Haeseler A,</li> <li>Posch AE: Species Identification and Antibiotic Resistance Prediction by Analysis of Whole-</li> <li>Genome Sequence Data by Use of ARESdb: an Analysis of Isolates from the Unyvero Lower</li> <li>Respiratory Tract Infection Trial. Journal of clinical microbiology 2020, 58(7).</li> <li>Dötsch A, Becker T, Pommerenke C, Magnowska Z, Jänsch L, Häussler S: Genomewide</li> <li>identification of genetic determinants of antimicrobial drug resistance in Pseudomonas</li> <li>aeruginosa. Antimicrobial agents and chemotherapy 2009, 53(6):2522-2531.</li> </ul>	905		Mol Ther Nucleic Acids 2019, <b>16</b> :218-228.
907Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside908acetyltransferase. Nat Med 2006, 12(1):83-88.909128.909128.910Posch AE: Species Identification and Antibiotic Resistance Prediction by Analysis of Whole-911Genome Sequence Data by Use of ARESdb: an Analysis of Isolates from the Unyvero Lower912Respiratory Tract Infection Trial. Journal of clinical microbiology 2020, 58(7).913129.914Dötsch A, Becker T, Pommerenke C, Magnowska Z, Jänsch L, Häussler S: Genomewide915aeruginosa. Antimicrobial agents and chemotherapy 2009, 53(6):2522-2531.	906	127.	Robicsek A, Strahilevitz J, Jacoby GA, Macielag M, Abbanat D, Park CH, Bush K, Hooper DC:
908acetyltransferase. Nat Med 2006, 12(1):83-88.909128.909128.910Posch AE: Species Identification and Antibiotic Resistance Prediction by Analysis of Whole-911Genome Sequence Data by Use of ARESdb: an Analysis of Isolates from the Unyvero Lower912Respiratory Tract Infection Trial. Journal of clinical microbiology 2020, 58(7).913129.914identification of genetic determinants of antimicrobial drug resistance in Pseudomonas915aeruginosa. Antimicrobial agents and chemotherapy 2009, 53(6):2522-2531.	907		Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside
<ul> <li>Ferreira I, Beisken S, Lueftinger L, Weinmaier T, Klein M, Bacher J, Patel R, von Haeseler A, Posch AE: Species Identification and Antibiotic Resistance Prediction by Analysis of Whole- Genome Sequence Data by Use of ARESdb: an Analysis of Isolates from the Unyvero Lower Respiratory Tract Infection Trial. <i>Journal of clinical microbiology</i> 2020, 58(7).</li> <li>Dötsch A, Becker T, Pommerenke C, Magnowska Z, Jänsch L, Häussler S: Genomewide identification of genetic determinants of antimicrobial drug resistance in <i>Pseudomonas</i> <i>aeruginosa</i>. <i>Antimicrobial agents and chemotherapy</i> 2009, 53(6):2522-2531.</li> </ul>	908		acetyltransferase. Nat Med 2006, 12(1):83-88.
910Posch AE: Species Identification and Antibiotic Resistance Prediction by Analysis of Whole-911Genome Sequence Data by Use of ARESdb: an Analysis of Isolates from the Unyvero Lower912Respiratory Tract Infection Trial. Journal of clinical microbiology 2020, 58(7).913129.914Dötsch A, Becker T, Pommerenke C, Magnowska Z, Jänsch L, Häussler S: Genomewide915aeruginosa. Antimicrobial agents and chemotherapy 2009, 53(6):2522-2531.916	909	128.	Ferreira I, Beisken S, Lueftinger L, Weinmaier T, Klein M, Bacher J, Patel R, von Haeseler A,
911Genome Sequence Data by Use of ARESdb: an Analysis of Isolates from the Unyvero Lower912Respiratory Tract Infection Trial. Journal of clinical microbiology 2020, 58(7).913129.914Dötsch A, Becker T, Pommerenke C, Magnowska Z, Jänsch L, Häussler S: Genomewide914identification of genetic determinants of antimicrobial drug resistance in Pseudomonas915aeruginosa. Antimicrobial agents and chemotherapy 2009, 53(6):2522-2531.	910		Posch AE: Species Identification and Antibiotic Resistance Prediction by Analysis of Whole-
912Respiratory Tract Infection Trial. Journal of clinical microbiology 2020, 58(7).913129.914Dötsch A, Becker T, Pommerenke C, Magnowska Z, Jänsch L, Häussler S: Genomewide914identification of genetic determinants of antimicrobial drug resistance in Pseudomonas915aeruginosa. Antimicrobial agents and chemotherapy 2009, 53(6):2522-2531.916	911		Genome Sequence Data by Use of ARESdb: an Analysis of Isolates from the Unyvero Lower
<ul> <li>913 129. Dötsch A, Becker T, Pommerenke C, Magnowska Z, Jänsch L, Häussler S: Genomewide</li> <li>914 identification of genetic determinants of antimicrobial drug resistance in <i>Pseudomonas</i></li> <li>915 <i>aeruginosa</i>. Antimicrobial agents and chemotherapy 2009, 53(6):2522-2531.</li> </ul>	912		Respiratory Tract Infection Trial. Journal of clinical microbiology 2020, 58(7).
<ul> <li>914 identification of genetic determinants of antimicrobial drug resistance in <i>Pseudomonas</i></li> <li>915 <i>aeruginosa</i>. Antimicrobial agents and chemotherapy 2009, <b>53</b>(6):2522-2531.</li> <li>916</li> </ul>	913	129.	Dötsch A, Becker T, Pommerenke C, Magnowska Z, Jänsch L, Häussler S: <b>Genomewide</b>
915 <i>aeruginosa</i> . Antimicrobial agents and chemotherapy 2009, <b>53</b> (6):2522-2531.	914		identification of genetic determinants of antimicrobial drug resistance in Pseudomonas
916	915		aeruginosa. Antimicrobial agents and chemotherapy 2009, 53(6):2522-2531.
	916		

#### 917 Tables

### Table 1. Summary of antimicrobial resistance prevalence across 10 clinically relevant antibiotics in

## 919 the *Pseudomonas aeruginosa* Global Dataset

Antibiotic Class	Antibiotic	Res (%)	Int (%)	Sen (%)	No. isolates
Carbapenems	MEM	682 (36)	149 (8)	682 (36)	1875
	IPM	186 (29)	46 (7)	419 (64)	651
Polymyxins	CST	48 (5)	0 (0)	933 (95)	981
Fluoroquinolones	CIP	664 (54)	78 (6)	477 (39)	1219
Cenhalosporins	FEP	157 (17)	111(12)	650 (71)	918
cephalosponns	CAZ	316 (27)	121 (10)	733 (63)	1170
Penicillins	TZP	179 (24)	52 (7)	526 (69)	757
	PIP	185 (36)	55 (11)	272 (53)	512
Aminoglycosides	ТОВ	294 (29)	12 (1)	695 (69)	1001
	АМК	170 (12)	56 (4)	1199 (84)	1425

920

921 Abbreviations: Res, resistant; Int, intermediate; Sen, sensitive; MEM, meropenem; IPM, imipenem;

922 CST, colistin; CIP, ciprofloxacin; FEP, cefepime; CAZ, ceftazidime, TZP, piperacillin/tazobactam; PIP,

923 piperacillin; TOB, tobramycin; AMK, amikacin

924 Table 2. Novel antimicrobial resistance (AMR) variants identified in *Pseudomonas aeruginosa* by

925	microbial genome-wide associa	tion study (mGWAS) c	or comparative genomic <sup>®</sup>	analyses
-----	-------------------------------	----------------------	-------------------------------------	----------

PA0027         Lys34Asn         PIPr         <	Locus	Type of mutation	Associated AMR phenotype	Fisher's Exact <i>p</i> value
PA0091 (vgrG1)         Gin214His         AMKi         NA           PA0746         Lys106Asn         FEPr         <0.0001	PA0027	Lys34Asn	PIPr	< 0.0001
PA0746         Lys106Asn         FEPr         < 0.0001           PA0958 (oprD)         Thr13fs <sup>10</sup> MEMr, IPMr         NA           PA0958 (oprD)         Leu136Gin <sup>10</sup> MEMr         NA           PA0958 (oprD)         Leu136Gin <sup>10</sup> MEMr         NA           PA0958 (oprD)         Gly139fs <sup>10*</sup> MEMr, IPMr         NA           PA0958 (oprD)         Leu309fro <sup>10</sup> MEMr         NA           PA0958 (oprD)         Leu309fro <sup>10*</sup> MEMr         NA           PA0958 (oprD)         Leu309fro <sup>10*</sup> MEMr         NA           PA1436 (cher)         Val81Ala         CSTr         NA           PA1436 (cher)         Alg38dy <sup>2</sup> CSTr         NA           PA1798 (parS)         Arg383Cys <sup>2</sup> CSTr         NA           PA1798 (parS)         Arg381Cys <sup>2</sup> CSTr         NA           PA1798 (parS)         Arg381Cys <sup>2</sup> CSTr         NA           PA1798 (parS)         Arg381Cys	PA0091 (vgrG1)	Gln214His	АМКі	NA
PA0958 (oprD)         Thr18fs <sup>2*</sup> MEMr, IPMr         NA           PA0958 (oprD)         Leu136GIn <sup>41</sup> MEMr, IPMr         NA           PA0958 (oprD)         Leu136GIn <sup>41</sup> MEMr, IPMr         NA           PA0958 (oprD)         Gly139fs <sup>41*</sup> MEMr, IPMr         NA           PA0958 (oprD)         Gly136fs <sup>45*</sup> MEMr, IPMr         NA           PA0958 (oprD)         Leu355fs <sup>3*</sup> MEMr, IPMr         NA           PA0958 (oprD)         Leu409Pro <sup>4*</sup> MEMr         NA           PA1436 (cher)         Val81Ala         CSTr         NA           PA1478 (parS)         Alg149Thr         MEMr         NA           PA1798 (parS)         Alg249Ash <sup>41</sup> CSTr         NA           PA1798 (parS)         Arg383Cys <sup>41</sup> CSTr         NA           PA1798 (parS)         Arg7His <sup>45</sup> PIPr         NA           PA1798 (parS)         Arg7His <sup>45</sup> PIPr         NA           PA1798 (parR) <td>PA0746</td> <td>Lys106Asn</td> <td>FEPr</td> <td>&lt; 0.0001</td>	PA0746	Lys106Asn	FEPr	< 0.0001
PA0958 (oprD)         Phe36fs <sup>H*</sup> MEMr, IPMr         NA           PA0958 (oprD)         Leu136Gln <sup>H</sup> MEMr         NA           PA0958 (oprD)         Gly139fs <sup>H*</sup> MEMr, IPMr         NA           PA0958 (oprD)         Gly139fs <sup>H*</sup> MEMr, IPMr         NA           PA0958 (oprD)         Tyr199fs <sup>H*</sup> MEMr, IPMr         NA           PA0958 (oprD)         Tyr195fs <sup>H*</sup> MEMr, IPMr         NA           PA0958 (oprD)         Leu35fs <sup>H*</sup> MEMr, IPMr         NA           PA0958 (oprD)         Leu40Pro <sup>H</sup> MEMr         NA           PA0958 (oprD)         Leu35fs <sup>H*</sup> MEMr, IPMr         NA           PA0958 (oprD)         Leu40Pro <sup>H</sup> MEMr         NA           PA1950 (oars)         Glu183Gly <sup>H</sup> CSTr         NA           PA1456 (chery)         Val81Ala         CSTr         NA           PA1798 (parS)         Ala149Thr         MEMr         <0.0001	PA0958 (oprD)	Thr18fs <sup>®^</sup>	MEMr, IPMr	NA
PA0958 (oprD)         Leu136GIn <sup>III</sup> MEMr         NA           PA0958 (oprD)         Gly139fs <sup>III</sup> MEMr, IPMr         NA           PA0958 (oprD)         Gly193fs <sup>III</sup> MEMr, IPMr         NA           PA0958 (oprD)         Gly193fs <sup>III</sup> MEMr, IPMr         NA           PA0958 (oprD)         Gly193fs <sup>III</sup> MEMr, IPMr         NA           PA0958 (oprD)         Leu35fs <sup>III</sup> MEMr, IPMr         NA           PA0958 (oprD)         Leu35fs <sup>III</sup> MEMr, IPMr         NA           PA0958 (oprD)         Leu35fs <sup>III</sup> MEMr, IPMr         NA           PA0958 (oprD)         Leu409Pro <sup>III</sup> MEMr         NA           PA1308 (lasR)         Glu183Gly <sup>III</sup> CSTr         NA           PA1456 (cheY)         Val81Ala         CSTr         NA           PA1798 (parS)         Alg38Cys <sup>III</sup> CSTr         NA           PA1798 (parS)         Arg383Cys <sup>III</sup> CSTr         NA           PA1798 (parS)         Arg383Cys <sup>III</sup> PIPr         NA           PA1798 (parS)         Arg383Cys <sup>III</sup> PIPr         NA           PA1798 (parR)         Val68Ala         CA2r         0.0001           PA1798 (parR) </td <td>PA0958 (oprD)</td> <td>Phe36fs<sup>₽^</sup></td> <td>MEMr, IPMr</td> <td>NA</td>	PA0958 (oprD)	Phe36fs <sup>₽^</sup>	MEMr, IPMr	NA
PA0958 (oprD)         Gly139fs <sup>III</sup> MEMr, IPMr         NA           PA0958 (oprD)         Gly139fs <sup>III</sup> MEMr, IPMr         NA           PA0958 (oprD)         Ty199fs <sup>III</sup> MEMr, IPMr         NA           PA0958 (oprD)         Gly139fs <sup>III</sup> MEMr         NA           PA0958 (oprD)         Lu350fs <sup>III</sup> MEMr         NA           PA0958 (oprD)         Leu355fs <sup>IIII</sup> MEMr, IPMr         NA           PA0958 (oprD)         Leu355fs <sup>IIII</sup> MEMr, IPMr         NA           PA0958 (oprD)         Leu359fs <sup>IIII</sup> MEMr, IPMr         NA           PA0958 (oprD)         Leu359fs <sup>IIII</sup> MEMr, IPMr         NA           PA0958 (oprD)         Leu359fs <sup>IIII</sup> MEMr         NA           PA1430 (losR)         Glu183Gly <sup>III</sup> CSTr         NA           PA1795 (parS)         Ala149Thr         MEMr         NA           PA1798 (parS)         Arg3826ys <sup>III</sup> CSTr         NA           PA1798 (parS)         Asp249Asn <sup>III</sup> TZPr, AMKi         NA           PA1799 (parR)         Leu165Phe <sup>III</sup> MEMr         NA           PA1923         Ala350Val         TZPr         <0.0001	PA0958 (oprD)	Leu136Gln <sup>®</sup>	MEMr	NA
PA0958 (oprD)         Gly193fs <sup>m</sup> MEMr, IPMr         NA           PA0958 (oprD)         Tyr199fs <sup>B+</sup> MEMr, IPMr         NA           PA0958 (oprD)         Gln340Pro <sup>dl</sup> MEMr         NA           PA0958 (oprD)         Gln340Pro <sup>dl</sup> MEMr, IPMr         NA           PA0958 (oprD)         Leu35fs <sup>B+</sup> MEMr, IPMr         NA           PA0958 (oprD)         Leu35fs <sup>B+</sup> MEMr, IPMr         NA           PA0958 (oprD)         Leu409Pro <sup>H</sup> MEMr         NA           PA0958 (oprD)         Leu409Pro <sup>H</sup> MEMr         NA           PA1456 (cher)         Val81Ala         CSTr         NA           PA1798 (parS)         Ala149Thr         MEMr         <<0.0001	PA0958 (oprD)	Gly139fs <sup>≌^</sup>	MEMr, IPMr	NA
PA0958 (oprD)         Tyr199fs <sup>IIII</sup> MEMr, IPMr         NA           PA0958 (oprD)         Gln340Pro <sup>III</sup> MEMr         NA           PA0958 (oprD)         Tyr350fs <sup>IIII</sup> MEMr, IPMr         NA           PA0958 (oprD)         Leu355fs <sup>IIII</sup> MEMr, IPMr         NA           PA0958 (oprD)         Leu409Pro <sup>III</sup> MEMr         NA           PA0958 (oprD)         Leu409Pro <sup>III</sup> MEMr         NA           PA1430 (losR)         Glu183Gly <sup>III</sup> CSTr         NA           PA1760         LOf <sup>III</sup> TZPI         NA           PA1798 (parS)         Arg383Cys <sup>III</sup> CSTr         NA           PA1798 (parS)         Arg383Cys <sup>III</sup> CSTr         NA           PA1798 (parS)         Arg383Cys <sup>III</sup> CZr         NA           PA1798 (parS)         Arg24PAsn <sup>IIII</sup> TZPr, AMKi         NA           PA1798 (parR)         Val68Ala         CAzr         0.0002           PA1799 (parR)         Val68Ala         CAzr         0.0001           PA1923         Ala350val         TZPr         <0.0001	PA0958 (oprD)	Gly193fs <sup>≌^</sup>	MEMr, IPMr	NA
PA0958 (oprD)         Gin340Pro <sup>III</sup> MEMr         NA           PA0958 (oprD)         Tyr350fs <sup>IIII</sup> MEMr, IPMr         NA           PA0958 (oprD)         Leu355fs <sup>IIIII</sup> MEMr, IPMr         NA           PA0958 (oprD)         Leu409Pro <sup>III</sup> MEMr, IPMr         NA           PA1430 (lasR)         Glu183Gly <sup>III</sup> CSTr         NA           PA1456 (cheY)         Val81Ala         CSTr         NA           PA1760         LOF <sup>III</sup> TZPi         NA           PA1798 (parS)         Ala149Thr         MEMr         <0.0001	PA0958 (oprD)	Tyr199fs <sup>®^</sup>	MEMr, IPMr	NA
PA0958 (oprD)         Tyr350fs <sup>m</sup> MEMr, IPMr         NA           PA0958 (oprD)         Leu35fs <sup>m</sup> MEMr, IPMr         NA           PA0958 (oprD)         Leu409Pro <sup>m</sup> MEMr         NA           PA1430 (losR)         Glu183Gly <sup>m</sup> CSTr         NA           PA1456 (cheY)         Val81Ala         CSTr         NA           PA1760         LOF <sup>m</sup> TZPi         NA           PA1798 (parS)         Ala149Thr         MEMr         <0.0001	PA0958 (oprD)	GIn340Pro <sup>®</sup>	MEMr	NA
PA0958 (oprD)         Leu35fs <sup>m</sup> MEMr, IPMr         NA           PA0958 (oprD)         Leu409Pro <sup>B</sup> MEMr         NA           PA1430 (lasR)         Glu183Gly <sup>E</sup> CSTr         NA           PA1456 (cheY)         Val81Ala         CSTr         NA           PA1760         LOF <sup>B</sup> TZPi         NA           PA1798 (parS)         Ala149Thr         MEMr         <0.0001	PA0958 (oprD)	Tyr350fs <sup>®^</sup>	MEMr, IPMr	NA
PA0958 (oprD)         Leu409Pro <sup>III</sup> MEMr         NA           PA1430 (lasR)         Glu183Gly <sup>III</sup> CSTr         NA           PA1456 (cheY)         Val81Ala         CSTr         NA           PA1760         LOF <sup>III</sup> TZPi         NA           PA1798 (parS)         Ala149Thr         MEMr         <0.0001	PA0958 (oprD)	Leu355fs <sup>®^</sup>	MEMr, IPMr	NA
PA1430 (lasR)         Glu183Gly <sup>III</sup> CSTr         NA           PA1456 (cheY)         Val81Ala         CSTr         NA           PA1760         LOF <sup>III</sup> TZPi         NA           PA1798 (parS)         Ala149Thr         MEMr         <0.0001	PA0958 (oprD)	Leu409Pro <sup>®</sup>	MEMr	NA
PA1456 (cheY)Val81AlaCSTrNAPA1760LOF#TZPiNAPA1798 (parS)Ala149ThrMEMr<0.0001	PA1430 (lasR)	Glu183Gly <sup>®</sup>	CSTr	NA
PA1760         LOF <sup>II</sup> TZPi         NA           PA1798 (parS)         Ala149Thr         MEMr         < 0.0001	PA1456 (cheY)	Val81Ala	CSTr	NA
PA1798 (par\$)         Ala149Thr         MEMr         < 0.0001           PA1798 (par\$)         Arg383Cys <sup>®</sup> CSTr         NA           PA1798 (par\$)         Arg7His <sup>®</sup> PIPr         NA           PA1798 (par\$)         Asp249Asn <sup>®</sup> TZPr, AMKi         NA           PA1799 (par\$)         Val68Ala         CAZr         0.0002           PA1799 (par\$)         Leu165Phe <sup>®</sup> MEMr         NA           PA123         Ala350Val         TZPr         <0.0001	PA1760	LOF <sup>₽</sup>	ТΖРі	NA
PA1798 (parS)Arg383Cys <sup>III</sup> CSTrNAPA1798 (parS)Arg7His <sup>III</sup> PIPrNAPA1798 (parS)Asp249Asn <sup>III</sup> TZPr, AMKiNAPA1799 (parR)Val68AlaCAZr0.0002PA1799 (parR)Leu165Phe <sup>III</sup> MEMrNAPA1923Ala350ValTZPr<0.0001	PA1798 (parS)	Ala149Thr	MEMr	< 0.0001
PA1798 (parS)         Arg7His <sup>III</sup> PIPr         NA           PA1798 (parS)         Asp249Asn <sup>III</sup> TZPr, AMKi         NA           PA1799 (parR)         Val68Ala         CAZr         0.0002           PA1799 (parR)         Leu165Phe <sup>III</sup> MEMr         NA           PA1292         Ala350Val         TZPr         <0.0001	PA1798 (parS)	Arg383Cys <sup>®</sup>	CSTr	NA
PA1798 (parS)         Asp249Asn <sup>®</sup> TZPr, AMKi         NA           PA1799 (parR)         Val68Ala         CAZr         0.0002           PA1799 (parR)         Leu165Phe <sup>®</sup> MEMr         NA           PA123         Ala350Val         TZPr         <0.0001	PA1798 (parS)	Arg7His <sup>®</sup>	PIPr	NA
PA1799 (parR)         Val68Ala         CAZr         0.0002           PA1799 (parR)         Leu165Phe <sup>fff</sup> MEMr         NA           PA1923         Ala350Val         TZPr         <0.0001	PA1798 (parS)	Asp249Asn <sup>®</sup>	TZPr, AMKi	NA
PA1799 (parR)         Leu165Phe <sup>III</sup> MEMr         NA           PA1923         Ala350Val         TZPr         <0.0001	PA1799 (parR)	Val68Ala	CAZr	0.0002
PA1923Ala350ValTZPr< 0.0001PA19421LOFMEMr, IPMrNAPA2020 (mexZ)Thr32AsnMEMrNAPA2020 (mexZ)Ser19811eMEMrNAPA2020 (mexZ)Leu199ArgFEPrNAPA2020 (mexZ)Leu199ArgFEPrNAPA2020 (mexZ)Leu199ArgCSTrNAPA2402Val3040AlaAMKr< 0.0001	PA1799 (parR)	Leu165Phe <sup>₽</sup>	MEMr	NA
$PA1942^1$ LOFMEMr, IPMrNA $PA2020 (mexZ)$ Thr32AsnMEMrNA $PA2020 (mexZ)$ Ser198IIeMEMrNA $PA2020 (mexZ)$ Leu199ArgFEPrNA $PA2402$ Val3040AlaAMKr<0.0001	PA1923	Ala350Val	TZPr	< 0.0001
PA2020 (mexZ)Thr32AsnMEMrNAPA2020 (mexZ)Ser198lleMEMrNAPA2020 (mexZ)Leu199ArgFEPrNAPA2020 (mexZ)Leu199ArgFEPrNAPA2402Val3040AlaAMKr<0.0001	PA1942 <sup>1</sup>	LOF <sup>₽</sup>	MEMr, IPMr	NA
PA2020 (mexZ)         Ser198lle <sup>III</sup> MEMr         NA           PA2020 (mexZ)         Leu199Arg <sup>III</sup> FEPr         NA           PA2402         Val3040Ala         AMKr         <0.0001	PA2020 (mexZ)	Thr32Asn <sup>®</sup>	MEMr	NA
PA2020 (mexZ)Leu199ArgFEPrNAPA2402Val3040AlaAMKr< 0.0001	PA2020 (mexZ)	Ser198lle <sup>₽</sup>	MEMr	NA
PA2402Val3040AlaAMKr $< 0.0001$ PA2520 (czcA)Gly1051Asp <sup>III</sup> CSTrNAPA2736Arg30GlyAMKr $< 0.0001$ PA3047 (PBP4, dacB)Thr27SerCAZr, FEPr, PIPr, TZPrNAPA3047 (PBP4, dacB)Ser230IIeCAZr, FEPr, PIPr, TZPrNAPA3047 (PBP4, dacB)Ser230IIeCAZr, FEPr, PIPr, TZPrNAPA3047 (PBP4, 	PA2020 (mexZ)	Leu199Arg <sup>®</sup>	FEPr	NA
PA2520 (czcA)Gly1051AspCSTrNAPA2736Arg30GlyAMKr<0.0001	PA2402	Val3040Ala	AMKr	< 0.0001
PA2736Arg30GlyAMKr< 0.0001PA3047 (PBP4, dacB)Thr27SerCAZr, FEPr, PIPr, TZPrNAPA3047 (PBP4, dacB)Ser230lleCAZr, FEPr, PIPr, TZPrNAPA3047 (PBP4, dacB)Phe438LeuCAZr, FEPr, PIPr, TZPrNAPA3047 (PBP4, dacB)Phe438LeuCAZr, FEPr, PIPr, TZPrNAPA3083 (pepN)LOF <sup>EI</sup> MEMr, CAZrNAPA3384 (phnC)LOF <sup>EI</sup> MEMr, TOBrNAPA3574 (nalD)Leu76Pro <sup>EI</sup> MEMrNAPA3574 (nalD)Arg164Pro <sup>EI</sup> PIPr, FEPrNAPA3721 (nalC)Lys58Glu <sup>EI</sup> MEMrNA	PA2520 (czcA)	Gly1051Asp <sup>®</sup>	CSTr	NA
PA3047 (PBP4, dacB)Thr27SerCAZr, FEPr, PIPr, TZPrNAPA3047 (PBP4, dacB)Ser230lleCAZr, FEPr, PIPr, TZPrNAPA3047 (PBP4, dacB)Phe438LeuCAZr, FEPr, PIPr, TZPrNAPA3083 (pepN)LOF <sup>III</sup> MEMr, CAZrNAPA3083 (pepN)LOF <sup>III</sup> MEMr, TOBrNAPA3574 (nalD)Leu76Pro <sup>III</sup> MEMrNAPA3574 (nalD)Arg164Pro <sup>III</sup> PIPr, FEPrNAPA3721 (nalC)Lys58Glu <sup>III</sup> MEMrNA	PA2736	Arg30Gly	AMKr	< 0.0001
dacB)IntersetOrder, FEPr, PIPr, TZPrNAPA3047 (PBP4, dacB)Ser230lleCAZr, FEPr, PIPr, TZPrNAPA3047 (PBP4, dacB)Phe438LeuCAZr, FEPr, PIPr, TZPrNAPA3083 (pepN)LOF $\mathbb{P}$ MEMr, CAZrNAPA3384 (phnC)LOF $\mathbb{P}$ MEMr, TOBrNAPA3574 (nalD)Leu76Pro $\mathbb{P}$ MEMrNAPA3574 (nalD)Arg164Pro $\mathbb{P}$ PIPr, FEPrNAPA3721 (nalC)Lys58Glu $\mathbb{P}$ MEMrNA	PA3047 (PBP4,	Thr27Ser	CA7r FFPr PIPr T7Pr	
PA3047 (PBP4, dacB)Ser230lleCAZr, FEPr, PIPr, TZPrNAPA3047 (PBP4, dacB)Phe438LeuCAZr, FEPr, PIPr, TZPrNAPA3083 (pepN)LOF <sup>III</sup> MEMr, CAZrNAPA3384 (phnC)LOF <sup>III</sup> MEMr, TOBrNAPA3574 (nalD)Leu76Pro <sup>III</sup> MEMrNAPA3574 (nalD)Arg164Pro <sup>III</sup> PIPr, FEPrNAPA3721 (nalC)Lys58Glu <sup>III</sup> MEMrNA	dacB)	11127301		NA
dacB)         NA           PA3047 (PBP4, dacB)         Phe438Leu         CAZr, FEPr, PIPr, TZPr         NA           PA3083 (pepN)         LOF <sup>III</sup> MEMr, CAZr         NA           PA3384 (phnC)         LOF <sup>III</sup> MEMr, TOBr         NA           PA3574 (nalD)         Leu76Pro <sup>III</sup> MEMr         NA           PA3574 (nalD)         Leu76Pro <sup>III</sup> MEMr         NA           PA3574 (nalD)         Leu76Pro <sup>III</sup> MEMr         NA           PA3574 (nalD)         Arg164Pro <sup>III</sup> PIPr, FEPr         NA           PA3721 (nalC)         Lys58Glu <sup>III</sup> MEMr         NA	PA3047 (PBP4,	Ser230lle	CAZr, FEPr, PIPr, TZPr	
PA3047 (PBP4, dacB)Phe438LeuCAZr, FEPr, PIPr, TZPrNAPA3083 (pepN)LOF <sup>III</sup> MEMr, CAZrNAPA3384 (phnC)LOF <sup>III</sup> MEMr, TOBrNAPA3574 (nalD)Leu76Pro <sup>III</sup> MEMrNAPA3574 (nalD)Arg164Pro <sup>III</sup> PIPr, FEPrNAPA3721 (nalC)Lys58Glu <sup>III</sup> MEMrNA	dacB)			NA
DAGES         NA           PA3083 (pepN)         LOF <sup>B</sup> MEMr, CAZr         NA           PA3384 (phnC)         LOF <sup>B</sup> MEMr, TOBr         NA           PA3574 (nalD)         Leu76Pro <sup>B</sup> MEMr         NA           PA3574 (nalD)         Arg164Pro <sup>B</sup> PIPr, FEPr         NA           PA3721 (nalC)         Lys58Glu <sup>B</sup> MEMr         NA	PA3047 (PBP4,	Phe438Leu	CAZr, FEPr, PIPr, TZPr	NIA
PA3003 (pept)         LOT         MEMI, CA21         NA           PA3384 (phnC)         LOF <sup>E</sup> MEMr, TOBr         NA           PA3574 (nalD)         Leu76Pro <sup>E</sup> MEMr         NA           PA3574 (nalD)         Arg164Pro <sup>E</sup> PIPr, FEPr         NA           PA3721 (nalC)         Lys58Glu <sup>E</sup> MEMr         NA	PA3083 (penNI)	LOF	MEMr CAZr	
PA3574 (nalD)         Leu76Pro <sup>™</sup> MEMr         NA           PA3574 (nalD)         Leu76Pro <sup>™</sup> PIPr, FEPr         NA           PA3574 (nalD)         Arg164Pro <sup>™</sup> PIPr, FEPr         NA           PA3721 (nalC)         Lys58Glu <sup>™</sup> MEMr         NA	PA3381 (nhnC)			
PA3574 (ndb)         Learborno         MEMI         NA           PA3574 (ndb)         Arg164Pro <sup>®</sup> PIPr, FEPr         NA           PA3721 (ndlC)         Lys58Glu <sup>®</sup> MEMr         NA	PA3574 (princ)		MEMr	
PA3721 (nalc)Lys58Glu $^{B}$ MEMrNAPA4030 (mml)Chu1235 cm $^{B}$ CA7m	PA3574 (nalp)			
	PA3721 (nalC)		MEMr	
	PA4020 (mol)	Glv137Ser <sup>®</sup>	CAZr	

PA4109 (ampR)	Ter297Tvr stop lost <sup>®^</sup>	PIPr	NA
PA4110 (ampC)	Asp272Asn <sup>®</sup>	MEMr	NA
$PA4110 (ampC)^2$	Leu320Pro <sup>®</sup>	MEMr	NA
PA4260 (rplB)	Glv138Ser <sup>®</sup>	TOBI. AMKr	NA
PA4266 (fusA1) <sup>#</sup>	Ser459Phe <sup>®</sup>	TOBr. AMKr	NA
PA4296 (pprB)	Asn253His <sup>®</sup>	CSTr	NA
PA4318	Pro243Ser	PIPr	< 0.0001
PA4418 (ftsl)	Gly63Asp <sup>®</sup>	IPMr, CAZr, FEPr, TZPr, PIPr	NA
PA4522 (ampD)	Val10Gly <sup>®</sup>	CAZr, FEPi, PIPi	NA
PA4522 (ampD)	Pro41Leu <sup>®</sup>	PIPr, FEPr	NA
PA4522 (ampD)	Glu67stop <sup>®^</sup>	CAZi, MEMi, IPMi, TZPi, PIPi, FEPi	NA
PA4522 (ampD)	Ile69Thr <sup>®</sup>	MEMr	NA
PA4522 (ampD)	Gln88Leu <sup>®</sup>	CAZr	NA
PA4522 (ampD)	Gly100Glu <sup>®</sup>	MEMr	NA
PA4522 (ampD)	Cys110Gly <sup>®</sup>	FEPr	NA
PA4522 (ampD)	Gly116Val <sup>®</sup>	MEMr, CAZr	NA
PA4522 (ampD)	Ile117Thr <sup>®</sup>	CAZr	NA
PA4522 (ampD)	Gly121Glu <sup>®</sup>	MEMr, CAZi	NA
PA4522 (ampD)	His157Tyr <sup>®</sup>	CAZr	NA
PA4522 (ampD)	Gly169Cys <sup>®</sup>	FEPr	NA
PA4599 (mexC)	-58C>A <sup>ℤ</sup>	FEPr	NA
PA4677	Asp138Val	FEPr	< 0.0001
PA4776 (pmrA)	Leu72Phe <sup>®</sup>	CSTr	NA
PA4777 (pmrB)	Arg10Leu <sup>ℤ</sup>	CSTr	NA
PA4777 (pmrB)	Arg155His <sup>®</sup>	CSTr	NA
PA4777 (pmrB)	Thr158Ile <sup>®</sup>	CSTr	NA
PA4777 (pmrB)	Thr253Met <sup>®</sup>	CSTr	NA
PA5000 (wapR)	Gly163Asp <sup>®</sup>	CSTr	NA
PA4967 (parE)	Glu459Lys	CIPi	NA
PA4967 (parE)	Val520Ala	CIPi	NA
PA5045 (ponA)	Met671lle	CAZr, FEPr, TZPr, PIPr	NA
PA5051 (argS)	Asp184Gly	TOBr	NA
PA5199 (amgS)	Trp120Gly <sup>®</sup>	CSTr	NA
PA5199 (amgS)	Pro435Ala <sup>®</sup>	CSTr	NA
PA5338 (spoT)	Gly496Ser <sup>®</sup>	CAZr	NA
PA5493 (polA)	Lys395Arg <sup>®</sup>	AMKr	NA

926 Abbreviations: AMK, amikacin; CAZ, ceftazidime; CIP, ciprofloxacin; CST, colistin; FEP, cefepime; fs,

927 frameshift; i, intermediate resistant; IPM, imipenem; LOF, loss of function; MEM, meropenem; NA, not

928 applicable; PIP, piperacillin; r, resistant; TOB, tobramycin; TZP, piperacillin/tazobactam

<sup>1</sup>Previously predicted to cause PIPr [129]; however, our microbial genome-wide associate study

- 930 (mGWAS) analysis did not identify a significant association with this phenotype. Instead, mGWAS
- 931 showed that this AMR variant was significantly associated with MEMr.

932 <sup>2</sup>Previously identified variant in *ampC* known to reduce susceptibility to multiple cephalosporins.

933 <sup>B</sup>Variant identified by comparative genomics and thus not assessed for statistical significance.

<sup>#</sup>Identified in the Validation Dataset only.

<sup>935</sup> <sup>^</sup>High-consequence mutations occurring in this gene are automatically identified by ARDaP.





- 944 amikacin; CAZ, ceftazidime; CIP, ciprofloxacin; CST, colistin; FEP, cefepime; FQs, fluoroquinolones; IPM,
- 945 imipenem; MEM, meropenem; PIP, piperacillin; TZP, piperacillin/tazobactam; TOB, tobramycin. \*No
- 946 strains in the Validation Dataset exhibited CST AMR; as such, balanced accuracy could not be



947 calculated for this antibiotic.

#### 949 Figure 2. Precision and recall of ARDaP, abritAMR, AMRFinderPlus, and ResFinder across the Global

950 Dataset (*n*=1877 strains). Precision and recall metrics for both antimicrobial-sensitive and

- 951 antimicrobial-resistant strains were highest using ARDaP (A; range 73-96%) with abritAMR (B; range
- 952 54-62%), AMRFinderPlus (B; range 55-62%) and ResFinder (C; range 42-68%) all performing worse in

953 comparison. To enable comparison with existing AMR prediction software, isolates with intermediate

- 954 AMR were removed prior to analysis. Abbreviations: AMK, amikacin; CAZ, ceftazidime; CIP,
- 955 ciprofloxacin; CST, colistin; FEP, cefepime; FQs, fluoroquinolones; IPM, imipenem; MEM, meropenem;
- 956 PIP, piperacillin; TZP, piperacillin/tazobactam; TOB, tobramycin. N.B. Precision (resistance) is also
- 957 known as positive predictive value (PPV) and precision (sensitivity) is also known as negative predictive

958 value (NPV).











Precision (AMR) Recall (AMR)

Precision (sensitivity)